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Summary of thesis 
This research aims to identify potential biomarker candidate(s) for CRC metastasis while 
performing a detailed investigation of its underlying mechanisms. Preliminary proteomics 
based experiments on CRC cell lines of different metastatic potentials provided an overall 
proteome signature of CRC metastasis as well as showed good correlation of intra-
cellular CacyBP (Calcyclin Binding Protein, causes degradation of β-catenin) level with 
metastasis. Preliminary functional studies suggested decreased cellular adhesion due to 
enhanced degradation of β-catenin as one of the causes behind this fact. Enhanced level 
of CacyBP and its direct association with CRC metastasis was further reinforced by the 
metastatic signature presented by CacyBP-overexpressed primary and CacyBP-
knockdown metastatic CRC cells. Subsequent iTRAQ based experiments on the whole 
cell lysate from these cells (CacyBP-overexpressed primary and CacyBP-knockdown 
metastatic CRC cells) confirmed that CacyBP enhances metastatic nature of CRC by 
various mechanisms such as increased endocytosis of integrins and its recycling to the 
leading edge of the cell, enhancing actin nucleation etc. In short this study proposed 
CacyBP as one of the potential candidate biomarker protein for CRC metastasis and also 
shed light on the possible mechanism by which this protein promotes CRC metastasis 
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1.1. Introduction  
Colorectal Cancer (CRC) is one of the major killers among all the existing cancers in this 
world. As per the cancer statistics in 2008, it is the second most common cause of death 
in the world [1, 2] and the third most common cause of malignancy in United the States 
[3, 4]. Although the survival rates were improved with the advancement of therapeutic 
strategies in the last decade, the disease recurrence and metastasis (spreading of primary 
tumor in organs other than the organ of origin) is yet to be combated. This leads to the 
increasing research interest about the underlying molecular mechanism as well as 
biomarker studies in this field. Proteomics along with other global approaches offer CRC 
research a new era providing wealth of new information regarding relevant proteins [5]. 
However, there are only limited numbers of reports regarding the disease progression and 
metastasis on CRC till date. The currently available records (discussed in detail in the 
review of literature section) only reported list of proteins rather discussing the inherent 
mechanisms involved and how it is affected by the proteins of interest. Therefore in spite 
of the availability of research articles describing proteomics in CRC metastasis, certain 
gaps remain in this field that can be reduced if not completely removed with further 
studies using improved model system as well as advanced technologies. 
This thesis describes proteomics studies on CRC metastasis using high-throughput 
proteomics application on cell based model systems. Use of cell based model system 
provides high sample homogeneity which is very useful at the discovery phase for 
selecting new candidate proteins, whereas high-throughput proteomics techniques 
provide wide range of protein identification within a short period of time. This 
introductory chapter defines the scope and aim of this study as well as describes the 
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disease stages and proteomics techniques applied, in detail for better understanding of the 
readers. Chapter 2 illustrates the experimentation as well as results for the initial 
discovery phase study which was performed in order to identify new candidate proteins 
for CRC metastasis. Chapter 3 focuses on the extended downstream studies on the 
potential candidate protein identified in chapter 2 and a plausible mechanism of how this 
protein is involved in CRC metastasis is suggested based on experimental observations. 
Chapter 4 describes the overall conclusion of the study and proposes some future 
directions of the project. 
1.2. Aim of study  
The main aim of this study is the identification and functional characterization of 
potential candidate biomarker(s) for CRC metastasis as well as detailed mechanistic 
investigation about the disease process. High-throughput proteomics techniques were 
used to identify new candidate proteins whereas the functional validation and mechanistic 
studies were performed using advanced molecular cell biology approaches. For better 
understanding, the aim is divided into the following objectives. 
 To identify potential candidate biomarker(s) for CRC metastasis, whole cell proteome 
from isogenic (derived from same patient at different stages of the disease) primary 
and metastatic CRC cell lines were compared using iTRAQ
TM
 (isobaric tags for 
relative and absolute quantitation) based proteomics experiment (discussed in chapter 
2).  
 To functionally validate the most promising protein candidate identified, transient 
gene knock-in studies were performed initially (discussed in chapter 2). 
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 To further functionally characterize the candidate protein, stable over-expression and 
knock-down was performed on CRC cells from different metastatic potential and 
metastatic signature was confirmed based on phenotypic assays performed on these 
genetically modified cells (discussed in chapter 3).   
 To investigate detailed underlying mechanism behind the involvement of this 
candidate protein in CRC metastasis, iTRAQ
TM
 based proteomics investigation on the 
whole cell proteome from the genetically modified stable cell lines were performed 
(discussed in chapter 3). 
1.3. Review of literatures  
This section generally describes the cancer biology and more specifically colorectal 
cancer biology and the use of high-throughput proteomics technologies in order to 
address the complexity of these diseases. 
1.3.1. Cancer  
Cancer is a complex disease that is caused by abnormal cell growth. However this is the 
simplest way to define this disease. In reality, the biological process by which normal 
cells are transformed into malignant cancerous cells is yet to be understood despite the 
vast research in this field from the past 4 decades. Confusions and contradictions have 
snowed under this field and without a definite idea about the reason causing this disease, 
there is no way to combat it. 
Twelve years ago, in a milestone review [6] six essential hallmarks were described as the 
cause of almost all types of cancer. These are self-sufficiency in growth signals, 
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insensitivity to growth-inhibitory (antigrowth) signals, evasion of programmed cell death 
(apoptosis), limitless replicative potential, sustained angiogenesis, and tissue invasion and 
metastasis. Among all types of cancer, colorectal cancer or CRC is the second most 
common cause of death in the developed world [1, 2] and the third-most common 
malignancy in the United States [3, 4] as mentioned previously in the introduction. 
1.3.2. Colorectal cancer (CRC)  
Colorectal cancer or CRC is a disease where cells in the colon (longest part of the large 
intestine) or rectum divides abnormally and forms a mass called tumor. Every year more 
than 1 million individuals develop this disease and the mortality rate is nearly 33% [7]. 
Estimated new cases and deaths from colon and rectal cancer in the United States in 2012 
are as follows [8]: New Cases- 103,170 (colon) and 40,290 (rectal); Deaths- 51,690 
(colon and rectal combined). Although current methods of clinical detection and 
screening of CRC have improved survival rates, almost 50% of the cases eventually turn 
out to be advanced stages of CRC leading to death within 5 years of diagnosis [9, 10].  
Colorectal cancer arises sporadically in most of the times. However, the major risk 
factors include old age, sex (male), previous history of colonic polyps or CRC and 
environmental factors such as food habits, obesity, smoking, high alcohol consumption 
etc [11]. About 6% of total occurrence of CRC was reported to be from the hereditary 
syndromes; 3% of which with Lynch syndrome, 2% with familial colorectal cancer non-
Lynch syndrome and about 1% constitute all of the others such as deletion in MSH2 (a 
gene that controls DNA nucleotide mismatch- repair system to correct errors that often 
occur during DNA replication) etc [12].  
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1.3.3. Stages of CRC (Past and present methods)  
For the improvement of patient care and better understanding of disease prognosis, CRC 
is classified into different stages based on the advancement of the disease state.    
 Past- Dukes classification: Cuthbert Dukes, a pathologist at St. Marks in London, 
was the first one to propose a simple classification scheme for rectal cancers in 1930s 
and it was later expanded to include colon tumors [13]. The system consisted of three 
stages: A, B, and C. Stage A tumors were confined to the rectal wall, stage B 
indicated spreading into extrarectal tissues without lymph node involvement, and 
stage C tumors had cancerous lymph nodes present. Later on he separated stage C 
into C1 and C2 where C1 stage represented extension of tumor through the perirectal 
tissue without lymph node involvement and C2 represented similar pattern with 
lymph node involvement. The first significant change to Dukes classification was 
made in 1949 by Kirklin et al [14] who proposed stage A as tumors confined to the 
mucosa and splitted stage B into two stages: B1 representing invasion into but not 
through the muscularis propia and B2 representing invasion through the muscularis 
propia. In the following decade, Astler and Coller redesigned Dukes original proposal 
about stage C sections [15] and in 1960s Turnbull [16] added stage D to the 
classification system and used this stage to illustrate distant disease and unresectable 
local disease [17]. Therefore as a result of these extensive modifications staging 
system turned quite complicated and hence in order to simplify it for wide application 
of patient care and research, TNM system has arrived which was first proposed in 
1954 and later adopted by the International Union Against Cancer (UICC) and the 
American Joint Committee on Cancer (AJCC) [17].  
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 Present- TNM system: The TNM or tumor-node-metastasis system majorly based on 
the anatomic extent of the disease and can be applied to both clinical (cTNM) and 
pathological (pTNM) staging [18]. Tumor stage is subdivided into 5 categories based 
on depth of bowel wall invasion. Stage Tis (in situ carcinoma) refers to the tumors 
restricted to the lamina propria without invading the submucosa. The T subcategories 
of a primary colorectal cancer are as follows (Figure 1.1.): T1- invasion into but not 
through the submucosa; T2- disease progression into but not through the muscularis 
propria; T3- invasion through the muscularis propria into surrounding subserosa 
(colon) or pericolonic adipose tissue; T4- invasion into other structures, T4a 
(perotonium) and T4b (adjacent organ). N group, one of the new features of the 
current AJCC 7
th
 edition, describes about the number of lymph nodes metastasis 
present in a patient risk group. N0- no evidence of nodal disease; N1- divided into 
two subclasses; N1a (one lymph node with metastasis) and N1b (two to three lymph 
nodes with metastases); N2- divided into N2a (four to six lymph nodes with 
metastases) and N2b (metastases in seven or more lymph nodes).  
This reflects deterioration of prognosis with increasing numbers of lymph nodes 
containing metastatic cancer. M group describes about distant metastasis; M0 where 












































Combining these three categories (TNM) the stage grouping system was made for better 
guidance on treatment planning. Patients with only in situ carcinoma are considered to 
have stage 0 disease which represents non-invasive tumors. Stage I disease corresponds 
to tumors with limited invasion of the bowel wall and no evidence of nodal or distant 
metastasis. On the contrary, the stage II disease represents those with more advanced 
bowel wall penetration but still lacking evidence on nodal or distant metastasis. Within 
Figure 1.1. Illustration of Tumor Stage Progression. T1- invasion into but not through the 
submucosa; T2- disease progression into but not through the muscularis propria; T3- invasion through 
the muscularis propria into surrounding subserosa; T4- invasion into other structures (Inspired by 
Horton J.K. et al. [17]) 
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this stage II group, patients with T3 stage are subclassified as IIA and with T4 as stage 
IIB because the degree of bowel wall penetration stands for a prognostic indicator. Stage 
III indicates all patients with nodal involvement and subclassified as IIIA- with limited 
bowel wall invasion (T1/2) and N1 nodal involvement; IIIB- with more advanced 
primary tumor (T3/4) associated with N1 disease and IIIC- presenting any degree of 
bowel wall invasion with ≥ 4 lymph node (N2) involvement. Stage IV indicates the 
patients with poorest prognosis corresponding to the presence of distant metastatic 
disease (M1) [19]. However, the TNM system is constantly undergoing modifications in 
order to create more specific demarcation between the prognostic groups. At present 
information regarding the prognostic markers of CRC is limited and a vast work is yet to 
be done. 
1.3.4. Metastasis- the spread of malignant cells from a primary tumor to distant sites  
Metastasis, the spreading of cancer cells from the primary tumor to a distant organ is the 
most common cause of death among cancer patients. The progression of metastasis 
involves complex underlying mechanism that consists of multiple steps. “Metastatic 
cascade” (Figure 1.2.) comprehensively summarizes all the steps involved in the 
metastasis process that can be listed as- i) epithelial- mesenchymal transition (EMT) that 
helped the primary cells to break the basement membrane barrier; ii) dissociation of 
tumor cells from the bulk tumor and invasion of the neighboring tissue; iii) intravasation 
into pre-existing and newly formed blood and lymph vessels; iv) transport through 
vessels; v) extravasation from vessels; vi) establishment of disseminated cells at a 
secondary anatomical site and finally vii) outgrowth of secondary tumors as micro/ 









To acquire metastatic phenotype, a primary adenocarcinoma cell must obtain migration 
and invasion characteristics to travel into adjacent tissues via blood or lymphatic vessels. 
This is associated with altered expression of several proteins involved in cell motility that 
triggers the response of the cells to the microenvironment. Hence these molecules have 
important roles in cell migration and motility and could be potential targets for anti-
metastasis therapy. Here we discuss several important phenomena and molecules 
associated with metastasis [21]. 
Figure 1.2.  The metastatic cascade: 0) Being induced by a distant tumor and mediated by bone 
marrow-derived cells, a “premetastatic niche” forms before metastasis becomes evident. 1) Cells in 
the primary tumor undergo Epithelial–Mesenchymal Transition (EMT) and acquire invasive 
properties. 2) Degradation of basement membranes and remodeling of the Extracellular Matrix 
(ECM) by proteinases facilitate tumor cell invasion. 3) Tumor cells invade surrounding tissue as 
single cells (3a) or collectively (3b). 4) Intravasation of tumor cells into newly formed vessels 
within or nearby the tumor. 5) Tumor cells are transported through the vasculature and arrest in a 
capillary bed where they extravasate (6). 7) Extravasated tumor cells can stay dormant for years. 8) 
Eventually, some disseminated cells grow out to a secondary tumor / macrometastasis, requiring 
ongoing ECM remodeling and angiogenesis (9). Cells outside their normal microenvironment 
undergo anoikis (“detachment-induced apoptosis”). Anoikis could hamper metastasis at several 
steps of the cascade, as indicated in the scheme. Not all steps of the metastatic cascade necessarily 
occur in a linear way. For example, premalignant tumors can already be vascularized while the 
timing of induction of the premetastatic niche remains elusive. (Adopted from Geiger, T.R. et al. 
[20] with permission) 
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1.3.4.1. Epithelial messenchymal transition (EMT)  
Epithelial tissues are composed of relatively rigid sheets of cells that are organized by 
lateral belts of cell-cell adhesion complexes and usually separated from the stroma by a 
basement membrane. During EMT, these epithelial cells release their attachment with 
their neighboring cells as well as basement membrane and thereby invade through 
surrounding tissues [22, 23]. As a characteristic, down-regulation of epithelial proteins 
such as E-cadherin, and catenin proteins that contribute to cell-cell adhesion is observed 
whereas mesenchymal proteins like N-cadherin, vimentin, tenascin C and various 
proteinases are up-regulated [24, 25]. EMT promotes metastasis in several ways, one of 
which include the loss of cell-cell adhesion that promotes the cells to initiate invasion 
[26]. 
1.3.4.2. Cell migration  
As described in the metastatic cascade (Figure 1.2.), migration assist the cells to continue 
the motion through the vascular bed and thereby contribute to metastasis. Recent 
advances in microscopic technologies, made it possible to study cell migration in vivo 
[27], which helps to interpret that cells acquire migrating behavior starting with the 
extension of cell membrane protrusions. This is mainly driven by a consecutive cycle of 
actin polymerization and de-polymerization in response to chemotactic signals [28]. 
Coffilin- dependent actin polymerization has been shown to act in synergy with the 
Arp2/3 complex to generate protrusions in response to EGF that are responsible for cell 
migration [29, 30]. Additionally, actin polymerization inducing proteins WASP (Wiskott-
Aldrich Syndrome protein) and N-WASP (neural WASP) were found to be important for 
the formation of cell protrusions [31-33]. Several upstream activators of N-WASP/ 
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WASP including Cdc42, Nck1 and WIP and a downstream effector, the Arp2/3 complex 
are known to affect pseudopod formation and hence tumor cell migration and metastasis 
[34-37]. Figure 1.3. showed the involvement of actin polymerizing proteins in tumor 
metastasis.  
During migration, the leading edge of cell body get attached to the extra- cellular matrix 
(ECM) fibers to pull the cell body forward [38]. This attachment involves dynamic 
changes in adhesion structures such as focal adhesion (FA) complex that involves up-
regulation of certain adhesion molecules like laminins and integrins [39, 40]. Surface 
receptors such as integrins start clustering when cells attach to ECM. The cytoplasmic 
domain of the clustered integrins act as a platform for the recruitment of cellular scaffold 
proteins such as talin, paxillin, tensin, α-actinin etc. that provide strong linkages between 
actin cytockeleton and ECM. The traction force necessary for cell movement, comes 
from this linkage [41-45]. Multiple phosphatase and kinases are also involved in integrin-
mediated signaling cascades that control cell migration [46, 47]. Subsequently, cells must 
detach from the ECM at the rear edge in order to continue movement. This requires 
disassembly of the FAs and subsequent internalization of integrins from the cell surface. 
These internalized integrins are either routed for lysosomal degradation or transported 
back from the rear to the leading edge via intracellular vesicle trafficking [48, 49] and 






















Figure 1.3.  Model of cell migration. A) Cells move forward by leading protrusions. B) 
WASP and Arp2/3 polymerize actin and facilitates cell migration. C) Integrin endocytosis 
at the rear end and their transportation to the leading edge helps the cell to move forward. 
(Inspired by Mohammad R. K. et al., [38] and [34,49]) 
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1.3.4.3. Cell invasion  
Invasive tumor cells can migrate either as single cells or as clusters or sheets. Within a 
migrating cluster, cadherins and other cell-cell adhesion proteins provide intercellular 
adhesion [50, 51]. Single cell migration either occurs as slow “mesenchymal” migration 
or faster “amoeboid” type migration [50]. Involvement of several signaling molecules 
and cell-cell adhesion molecules (CAMs) are reported to be important for cell invasion. 
For example N-CAM switches from a highly adhesive to a poorly adhesive isoform 
during invasion in several carcinomas as well as an overall reduction in expression level 
was observed to promote metastasis [6, 52]. Changes in integrin expression are also 
evident in invasive metastasis. During invasion, expression of integrin subtypes such as 
α3β1 and αVβ3 is increased preferentially and these subtypes bind to the degraded 
stromal components produced by extracellular proteases [53, 54]. Extracellular proteases 
are the next important molecules to be altered in expression level during invasion and 
metastasis. Protease genes are up-regulated whereas protease inhibitors are down-
regulated [55, 56]. 
1.3.4.4. Anoikis suppression 
 Anoikis is referred to as cell death induced by inappropriate or loss of cell adhesion, that 
is often being addressed by tumor cells at different stages of metastasis and is one of the 
barrier against it [57]. Anoikis suppression is therefore likely to be essential for 
successful metastasis [58]. Integrin signaling and anoikis are tightly linked to each other 
since integrins are the main cell surface receptors that bind to various ECM (Extra-
cellular matrix) molecules and triggers an intracellular signaling cascade in response [59, 
60]. Integrin activation protects the cells against anoikis [61]. 
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1.3.4.5. Angiogenesis  
To grow and survive at a distant site, metastatic cells require proper supply of nutrients 
and oxygen which demands for vascular growth around the tumor [62]. In most of the 
cases tumor vascularization is achieved by persistent angiogenesis (sprouting of new 
vessels from existing ones) with a significant contribution of bone marrow-derived 
vascular progenitor cells [63]. Both blood and lymphangiogenesis are essential 
phenomena to be triggered, once a tumor metastasizes.  
1.3.4.6. Enhanced calcium dynamics is associated with metastasis  
Ca
++
 signaling has been recognized as one of the important regulators of various cellular 
functions relevant for the acquisition of metastatic phenotype. It is also an important 
second messenger that bridge the cell-substrate interplay and the actin cytoskeleton [64-
66]. Bastatas et al identified that intracellular Ca
++
 dynamics is greater in highly 
metastatic cancer cells compared to cells with low metastatic potential [67]. Highly 
metastatic cells, that are more migratory in nature, usually exhibit transient gradients of 
intracellular Ca
++
 increasing from the leading (front) to the lagging (rear) edge which is 
responsible for rear-end retraction by myosin II contraction associated with Myosin 
Light-Chain (MLC) phosphorylation via Ca
++
-dependent MLC Kinase (MLCK) [68, 69]. 
This high calcium dynamics was activated by the elevated tension on the cell membrane 
produced by the focal adhesion (FAs) [70-72]. Disassembly of FAs at the lagging edge of 
the cell is conducted by calpain-mediated cleavage of FA proteins including vinculin, 
integrins, talin, and focal adhesion kinase [73]. Therefore, the morphological and 




1.3.5. Current diagnosis and treatment strategies for CRC; with special emphasis on 
metastatic CRC 
1.3.5.1. Diagnosis  
Colonoscopy and sigmoidoscopy along with tumor biopsy are the majorly used diagnosis 
approach for the primary detection of CRC. Usually, during the initial diagnosis, use of 
FDG-PET (Positron emission tomography with the 18-fluoro-2-deoxy-D glucose) is not 
recommended [74]. To detect metastatic disease, CT (Computed tomography) scan of 
chest, abdomen and pelvis is performed [75]. Use of other imaging methods such as 
ultrasound and MRI are also common for detection of metastasized tumors. However, 
detection of certain metastasized tumors such as peritoneal carcinomatosis (secondary 
tumor affecting the lining of the abdominal cavity, one of the susceptible regions for 
secondary tumor formation following colon cancer) still remains a challenge with the use 
of current diagnostic methods available and hence calls for improved diagnostic 
approaches. Once diagnosis is made, staging is described according to the TNM system 
[76]. 
1.3.5.2. Treatment by surgery  
For colon cancer, total resection of the tumor should be done with minimum distal 
margin of 5 cm. For proper detection of tumor stage, lymphadenectomy of at least 12 
lymph nodes should be performed. For invasive rectal cancer, total excision of the 
mesorectum (TME) with adequate circumferential and distal margin is carried out. TME 
is associated with a reduced risk of local recurrence and thereby is a remedy of choice for 
early rectal cancer patients [77-79].   
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Liver and lung are the most common sites of recurrence after surgery in CRC. Therefore 
resection of liver and lung metastases is the standard care therapy that may improve 5 to 
10 year of survival rates [12]. Radiotherapy and chemotherapy are used sometimes to 
convert unresectable tumors into resectable ones if the response to the therapy is good 
[80, 81]. 
1.3.5.3. Treatment by radiation  
Radiation therapy is implicated in order to avoid the risk of local failure in treatment of 
rectal cancer which is quite common after surgical resection due to the involvement of 
circumferential resection margin, lymph node status and extramural venous invasion [82]. 
In a German trial comparing the effect of pre- versus post-operative chemoradiation, it 
was reported that a significantly lower incidence of local recurrence and toxicity occurs 
in case of pre-operative chemoradiation [83]. Therefore the conventional treatment for T3 
and advanced stage of CRC in most of the countries is preoperative radiation treatment. 
Sometimes, adjuvant chemotherapy is applied with preoperative radiation treatment [12].  
1.3.5.4. Treatment of metastatic disease  
For treatment of liver only or lung only CRC metastases, palliative chemotherapy 
provides improved survival and better quality of life by reducing symptoms. Use of 
fluorouracil infusion with addition of irinotecan and oxaliplatin was most common [84]. 
However, in the past 5 years the treatment of metastatic disease was advanced with the 
use of targeted treatments with human EGFR (Epidermal growth factor receptor) or 
VEGF (Vascular endothelial growth factor) monoclonal antibodies (eg. cetuximab, 
bevacizumab and panitumumab are the only licensed targeted drugs). Cetuximab is active 
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enough when used alone and can hinder irinotecan-resistance when used as a 
combination therapy with irinotecan [85, 86]. Bevacizumab is an antiangiogenic 
monoclonal antibody that causes normalization of tumor vasculature and thereby 
improves targeted drug delivery, but it produces side effects such as bleeding, delayed 
wound healing, gastrointestinal perforation etc. However, the use of this drug in a 
combination therapy with fluorouracil and oxaliplatin did not show very reproducible 
results [87] and has little activity when used alone [88]. Thereby continuing the use of 
this drug after disease progression still remains a dubious issue. In general, anti-
EGFR/VEGF drugs showed improvement in overall survival and decelerates disease 
progression in patients with wild type KRAS colorectal cancer than mutated KRAS [89]. 
Combination therapy of Cetuximab with Capecitabine, oxaliplatin and bevacizumab and 
of panitumumab with bevacizumab, irinotecan or oxaliplatin in untreated patients with 
metastatic disease increased toxicity and worsen progression free survival, representing a 
negative outcome [90].  Bevacizumab passed the regulatory approval in 2004 for first-
line treatment of metastatic CRC in combination with fluoropyrimidine based 
chemotherapy and was widely used until cetuximab was granted approval for 
monotherapy or combination therapy in 2004 and panitumumab in 2006-2007 for 
monotherapy among pretreated patients with wild type KRAS tumors. However, the use 
of anti-EGFR drugs is quite restricted outside USA due to cost. For instance in UK, 
cetuximab was only approved by the National Institute for Health and clinical Excellence 
(NICE) for wild type KRAS non-resectable liver-only metastatic CRC [12, 91]. Hence, in 
spite of the availability of several advanced therapeutic strategies for metastatic CRC, 
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successful use of those with a positive outcome still remains a matter of dispute and 
demands for further investigation. 
1.3.6. Prognostic and predictive molecular markers of CRC-Current scenario 
Molecular markers for a disease can be either prognostic or predictive. Prognostic 
biomarkers are majorly associated with survival whereas predictive markers are the 
representative of the benefit of treatment strategies. The most important outcome about 
the molecular marker for CRC metastasis is the identification of KRAS mutation status as 
a predictive of non-response to EGFR targeted drugs. Roughly 40% of patients with 
metastatic CRC have KRAS mutation and thereby gives no response to the anti-EGFR 
therapy [89]. However, the remaining 60% of patients with wild type KRAS do not 
respond to the treatment fully. Mutation of BRAF or NRAS or loss of PTEN or PIK3CA 
activation might contribute to the resistance against EGFR targeted monoclonal 
antibodies [92]. BRAF is the main downstream effector of KRAS and mutation of BRAF 
is associated with poor prognosis in patients with metastatic CRC treated with EGFR 
antibodies [93] although the predictive value for this is yet to be assessed. 
High frequency microsatellite instability (MSH) is present in almost 22% of stage II and 
12% of stage III CRC [94]. Studies have shown that patients with high- frequency 
microsatellite instability did not show improved response when treated with adjuvant 
fluorouracil [95], suggesting that it can be a predictive marker for the fluorouracil based 
chemotherapy [94]. On the other hand the prognostic data for MSH instability showed 
contradictory results for the irrinotecan based chemotherapy [94, 96].  
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There are studies that showed an association between loss of heterozygosity at 
chromosome 18q with poor prognosis in CRC patients [97-100]. The 18q region contains 
several important candidate genes including SMAD7, SMAD4, SMAD2 and DCC. 
Reduced SMAD4 expression was associated with poor prognosis with fluorouracil based 
chemotherapy in stage III CRC patients. The investigation about the 18q and 
microsatellite instability status to connect with adjuvant therapy is still in progress. 
Thymidylate synthase (the primary target of the active metabolite of fluorouracil), 
excision-repair cross-complementing-1 (implicated in resistance or sensitivity to platinum 
drugs), VEGF and its receptors, and the interleukins are also extensively studied potential 
prognostic and predictive markers for CRC [12].  
However single markers might not be the entire representative due to the involvement of 
complex pathways and multiple genes in the disease process. This situation necessitates 
the use of high-throughput approaches like transcriptomics and proteomics for the 
screening of correlated biomarkers which is in full swing in recent years but not a single 
candidate has been validated yet for clinical use.  
1.3.7. High-throughput global screening approaches; from genomics to proteomics  
Though major improvements are achieved in the area of understanding disease 
mechanisms in past few years, certain gaps remain that are believed to be overcome by 
the application of high-throughput global screening approaches like genomics, 
trancriptomics and proteomics which are representatives of DNA, mRNA and protein 
dynamics of a cell, respectively. Although DNA and RNA act like a “blueprint” for 
corresponding proteins, neither of them confirms the prediction about the synthesis of the 
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proteins, the dynamic components of a cell [101].  Moreover, the structure, function and 
cellular localization of proteins are not sufficiently illustrated from the DNA and RNA 
sequences. In addition, studying at proteome level, allows for the detection of 
functionally important post-translational modifications which cannot be predicted from 
the genome and transcriptome level. These reasons make proteomics to be a favorable 
global screening technique over genomics and transcriptomics. Particularly, demarcation 
of altered protein expression in whole cell and/ or tissue level as well as in sub-cellular 
structures and biological fluids are the promising upshot of proteomics strategies that 
helps in the identification of novel biomarkers as well as therapeutic targets [102]. As 
described in a nature review article in 2003 [103], there are five major pillars in the area 
of proteomics research although these are overlapping to each other. These are mass 
spectrometry-based proteomics, proteome-wide biochemical assays, systematic structural 
biology and imaging techniques, proteome informatics, and clinical applications of 
proteomics. This thesis aims to apply the mass spectrometry-based proteomics for the 
clinical use of cancer metastasis. Thereby we focus our description mainly on the mass 
spectrometry based proteomics techniques available. For better understanding, a brief 
overview on mass spectrometric measurements is provided before the detailed proteomics 
techniques are discussed. 
1.3.8. Mass Spectrometry- principles and instrumentation 
On a conventional thought, mass spectrometry measures the masses of molecules by 
measuring their mass-to-charge (m/z) ratios in order to confirm the identity of a molecule. 
This is based on ion production, separation and detection. Usually the ionized particles 
are analyzed in gas phase. Mass spectrometers usually consist of an ionization source that 
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Ion Source Mass Analyzer Detector
is used to volatize and ionize the analytes, a mass analyzer that measures the mass-to-
charge ratio (m/z) of the ionized analytes, and a detector that records the number of ions 
at each m/z value. Other than these 3 fundamental components, mass spectrometers also 




However, with the introduction of soft ionization methods (discussed in following sub-
sections), mass spectrometry is widely in use for protein sequence identification since 
1990‟s and gained popularity over the traditional Edman sequencing due to its high 
accuracy and reduced time of analysis. Our study uses mass spectrometry for protein 
identification and quantitation. The following sub-sections describes the three 
fundamental components of a mass spectrometer with special emphasis on the principles 
and instrumentation that we used for our study. 
 Ion Source: This study uses two most popular ionization techniques used in a mass 
spectrometer for proteomics applications; i) matrix-assisted laser 
desorption/ionization (MALDI) and ii) electrospray ionization (ESI) [104, 105].  
i) MALDI: MALDI ionizes sublimed samples out of a dry, crystalline matrix via 
laser pulses. The laser pulse produces the following particles: Matrix neutrals 




 and Sample neutrals (A). The matrix ions 







 + A → M + (A+H)+ 
(M-H)
−
 + A → (A-H)− + M 
Figure 1.4.  Simple outline of a Mass Spectrometer: Analytes are ionized in the ion 





















































ii) ESI: ESI ions are produced at atmospheric pressure by applying sample dissolved 
in solvent to a narrow capillary tube, which is under the influence of an electric 
field. Due to the potential difference created between the capillary and the inlet of 
the mass spectrometer, the force generated forms a cone of fine droplets which 
subsequently reduced in size due to evaporation. However during this process the 
charge on the droplets remain constant that eventually cause the surface 
coulombic forces to exceed the surface tension ultimately leading to fission of 
droplets into smaller ones and this process continue until nanometer sized droplets 








Figure 1.5.  Simple schematic representation of the principle of ionization in MALDI. 
Laser induced ionization of sample occurs from a mixture of matrix and sample.  
Figure 1.6.  Simple schematic representation of the principle of ionization in ESI. 
Ions are produced at atmospheric pressure by applying sample dissolved in solvent to a 
narrow capillary tube, which is under the influence of an electric field. Ion droplets get 
reduced in size keeping the charge constant and eventually break apart until nanometer 






Heavy ion reaches detector last
 Mass Analyzer: The mass analyzer is the central part of the equipment. Five basic 
types of mass analyzer are currently used in proteomics research. These are the ion 
trap, time-of-flight (TOF), quadrupole, OrbiTrap and Fourier transform ion cyclotron 
(FT-MS) analyzers. Each of them is very different in design and performance and has 
its own strength and weakness. In context of proteomics research that demands for 
better sensitivity, high resolution, mass accuracy and the ability to generate 
information-rich ion mass spectra from peptide fragments, TOF and quadruple are the 
most common mass analyzers used individually or in combination. Our study also 
made the use of these two types of analyzers and their principles are described below. 
i) Time-of-flight analyzer (TOF): In this type of analyzers, ions produced in the 
ion source are accelerated by high voltage that results in an ion having the same 
kinetic energy as any other ion that has the same charge. The velocity of the ion 
depends on the mass-to-charge ratio. The time that is subsequently taken by the 
particle to reach a detector at a known distance is measured. This time depends on 
the mass-to-charge ratio of the particle (heavier particles take more time). From 
this time and the known experimental parameters one can find the mass-to-charge 







Figure 1.7.  Simple schematic representation of the principle of ion-separation in a 
TOF analyzer. Ions are separated based on the time taken by the ion to reach the 












ii) Quadrupole analyzer: As the name implies the quadrupole analyzer consists of 4 
circular rods, set parallel to each other. Ions are separated based on the stability of 
their trajectories in the oscillating electric fields that are applied to the rods. Each 
opposing rod pair is connected together electrically, and a radio frequency (RF) 
voltage is applied between one pair of rods and the other. A direct current voltage 
is then superimposed on the RF voltage. Ions travel down the quadrupole between 
the rods. Only ions of a certain mass-to-charge ratio m/z will reach the detector 
for a given ratio of voltages: other ions have unstable trajectories and will collide 
with the rods. This permits selection of an ion with a particular m/z or allows the 













Figure 1.8.  Simple schematic representation of the principle of ion-   
separation in a Quadrupole analyzer. Ions are separated based on the 
stability of their trajectories in the oscillating electric fields, applied to 













Use of hybrid analyzers has become popular from the beginning of this century especially 
for proteomics analysis. In our study we used two types of hybrid analyzers namely 4800 
MALDI-TOF/TOF analyzer (AB SCIEX) and 5600 TripleTOF analyzer (QqTOF; AB 
SCIEX). The quadrupole and TOF analyzers are used in series (Q-TOF) together with 
ESI ionization source. In a hybrid Q-TOF analyzer the collision cell is placed between a 
quadrupole mass filter and a TOF analyzer [108] whereas in case of a TOF-TOF 
analyzer, the collision cell is placed in between two TOF sections [109]. Ions of a 
particular m/z are selected in a first mass analyzer (TOF or quadrupole), fragmented in a 
collision cell and the fragment ion masses are „read out‟ by the second (TOF) analyzer. 
The resulting fragment ion spectra are often more extensive and informative than those 





 Protein identification using MS/MS spectra: Upon fragmentation under CID 
(collision induced dissociation), each peptide predominantly generates two 
complementary ion series consisting of i) the n-terminal ion series or b- ion series 
that contains the n- terminal amino acid and extensions from this residue and ii) the 
c- terminal ion series or y- ion series that contains the c- terminus of the peptide and 
the extensions from this residue. For example, the y-ion series of tryptic peptides will 
start with masses y1=147 (Lys) or 175 (Arg) and the next fragmentation peak in the y 
ion series. The y2 ion will contain an extra mass equal to the mass of an amino acid 
Figure 1.9.  Simple schematic representation of Tandem mass analyzer. Two or more 
analyzers are connected together and separated by a collision cell which fragments ion. 
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residue thereby identifying the next amino acid. An additional mass of the peptide 
backbone atoms is also to be considered. These information will then be combined in 
order to get a list of peptide sequences present in the sample mixture analysed. These 
peptides are searched against the existing protein database for a particular species in 
order to match against the proteins. Based on the protein hits the final protein list is 













1.3.9. High throughput mass spectrometry-based protein profiling approaches 
One of the important and obvious step for any MS based proteomics analysis is a 
systematic separation of proteins from a complex mixture which was done by either gel-
Figure 1.10. Protein and peptide identification through MS/MS analysis: A) Individual mass 
spectrum for a particular peptide; B) MS/MS spectrum generated upon collision induced dissociation 
(CID) from the individual peptide spectrum; C) The reporter ion region for tagging reagents (eg. 
iTRAQ, explained later) is shown in magnified version for the quantitation information 
43 
 
based or liquid chromatography (LC)-based approaches [111]. For the gel-based 
approaches, proteins were separated according to their pI and/ or molecular weight, 
detected by staining (mainly silver staining) and quantified based on the staining 
intensities of the band or the spot. Identification of proteins were then performed after 
cutting the spots or the bands, trypsin digestion and finally by mass spectrometry (MS). 
On the other hand, for the LC-based approaches, proteins were first digested and then 
separated by LC columns and then detected, identified and quantified by MS. The goal of 
initial proteomics research was mainly to identify and characterize proteins but with 
recent advances in chromatography, MS and bioinformatics, the goal has been extended 
to quantitative and comparative studies. 
During the early days of proteomics research, the major protein profiling technique used 
to be the gel-based approaches such as two-dimensional polyacrylamide gel 
electrophoresis (2D-PAGE/ 2-DE) [112] where the quantitation is made upon merging 
and comparing samples using a software. However, this method needs a number of 
replicate runs in order to avoid experimental errors [113] and displays only limited 
number of abundant proteins and thereby may exclude certain important protein 
information about the low abundant ones. An alternative to this protocol is difference gel 
electrophoresis (DIGE) where, the control and treated samples are individually labeled 
with different fluorescent dyes (e.g., Cy3 and Cy5, respectively) and a mixture of an 
equal amount of the control and treated samples is labeled with Cy2. The labeled samples 
are then combined and run in a single 2-D gel to allow better spot matching and minimize 
gel-to-gel variations. At the same time this method also allows multiplexing of upto 3 
samples in one run which is an added advantage. However in the last 10 years, these gel-
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based techniques were challenged as well as complemented by LC-based approaches 
especially in the area of high-throughput screening due to the issue of reproducibility 
[114], identification of low-abundant proteins [115], highly acidic or basic proteins or 
proteins with extreme size or hydrophobicity [116]. The gel-based approaches are 
difficult to automate whereas LC-based ones are fully automated [117]. 
LC-based methods also allow a wide range of combination of stationary and mobile 
phase for the separation of complex biological samples at the protein or peptide level 
[118, 119]. In a multidimensional LC approach, proteins are usually trypsin digested into 
peptides prior to separation first by cation exchange and followed by C18 reversed-phase 
chromatography providing the advantage of direct injection of samples from the C18 
column into a mass spectrometer. For the relative quantification of proteins or peptides in 
global level, several tagging methods are available that are based on LC-MS.  One of 
them is isotope-coded affinity tags (ICAT) [120]. Usually proteins from two comparable 
samples are labeled at cysteine residues with light- and heavy-tags carrying a biotin 
moiety respectively. The labeled proteins are then mixed, digested and excess reagents 
are removed through cation exchange chromatography followed by an affinity 
purification step using immobilized avidin. Peaks corresponding to the same peptide are 
identified as doublets in mass spectra due to the mass difference between light and heavy 
isotopes where the peak intensities of the peptides are taken as a representation of the 
relative abundance of the proteins in the two samples. However, ICAT has a number of 
limitations including missed identification of proteins with few or no cysteine residue, 
lost information for post-translational modifications, differential reversed-phase elution 
of identical peptides labeled with the hydrogen/ deuterium isotope pairs, and complicated 
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interpretation of tandem mass spectrometry (MS/MS) spectra due to the addition of the 
biotin group [121, 122]. Many of these limitations have been overcome by the new 
cleavable ICAT (cICAT) reagent that employs 
13
C isotopes and an acid-cleavable biotin 
group [123, 124]. Beside ICAT method, other LC/MS-based stable isotope coding 
techniques are reported in the literature as well [121]. One of these include stable isotope 
labeling by amino acids in cell culture (SILAC) where, in vivo incorporation of a mass 
difference is performed by the cell culture enrichment with stable isotope-labeled amino 
acid, including arginine, lysine, tyrosine and leucine [125-128]. All these methods impart 
a mass difference as the basis for quantitation by measuring the relative peak areas in MS 
and/ or MS/MS. However, all these mass difference concepts are designed to compare a 
binary set of data that make it difficult to analyze more than 2 samples together especially 
for time course analyses. Although multiple sets of 2-plex datasets can be combined after 
separate analysis, there will always be a possibility of identifying different sets of 
peptides and proteins between each experiment. In order to avoid this multiplexing issue, 
a 4-plex followed by 8-plex of isobaric tagging reagents were launched in 2004 [110] and 
2007 [129] by Applied Biosystems respectively. In fact, this relatively new quantitative 
labeling method called isobaric tags for relative and absolute quantitation (iTRAQ) has 
become quite popular in the last 8 years. This technique allows multiplexing upto 8 
samples by tagging at the N-termini of peptides and the lysine side chains, thereby 
labeling all peptides in a digest mixture through a set of amine reactive isobaric tags 
[110] and thus reducing the chance of skipping any peptide information including post-
translational modifications (PTM). In first MS, peptides labeled with any of the isobaric 
tags are indistinguishable whereas upon fragmentation in MS/MS, signature ions (m/z 
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values of 114.1, 115.1, 116.1, 117.1 for 4-plex, complemented with 113.1, 118.1, 119.1, 
121.1 for 8-plex) are identified which provide quantitative information about peptides 
upon integration of the peak areas [110]. In addition to the stable isotope-labeling 
approach, several researchers have developed alternative LC-based quantification 
strategies without any labeling [111, 130, 131]. 
In our study, we used the most popular labeling approach, iTRAQ (4plex) for comparing 
whole cell proteome from primary and metastatic CRC cells. The model of study and its 
efficacy is elaborated in next chapter. Choosing iTRAQ was effective for our study since 
it allowed the investigation of a pair of biological replicate from each sample together in 
a single 4-plex experiment.   
1.3.10. iTRAQ – Multiplexed tagging chemistry  
Since we used 4-plex iTRAQ reagents for all our proteomics studies, this section about 
tagging chemistry of iTRAQ reagents will primarily emphasize on 4-plex rather than 8-
plex reagents. iTRAQ reagents were designed as isobaric tags consisting of a charged 
reporter group (unique to each of the four reagent), a peptide reactive group and a neutral 
balance portion to maintain an overall mass of 145 (Figure 1.5.A). In short, the reporter 
group is based on N-methylpiperazine, the mass balance group on carbonyl, and a 
peptide-reactive group on NHS ester. The overall mass of reporter and balance 






O atoms (Figure 1.5.B), thus avoiding problems with chromatographic 
separation seen with enrichment involving deuterium substitution. The reporter group 
ranges in mass from m/z 114.1 to 117.1, while the balance group ranges in mass from 28 
to 31 Da, such that the combined mass remains constant (145.1 Da) for each of the four 
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reagents. When reacting with a peptide, the tag forms an amide linkage to any peptide 
amine (N-terminal or ε amino group of lysine). These amide linkages fragment in a 
similar fashion to backbone peptide bonds when subjected to CID. Following 
fragmentation of the tag amide bond, however, the balance (carbonyl) moiety is lost 
(neutral loss), while charge is retained by the reporter group fragment.  
A mixture of four identical peptides each labeled with one member of the multiplex set 
appears as a single, unresolved precursor ion in MS (identical m/z). Upon MS/ MS 
fragmentation, these reagents generate four unique (m/z values of 114.1, 115.1, 116.1, 
117.1 for 4-plex) that are used to quantitate relative abundance of a single peptide in all 4 
samples. This mass range has minimal contamination with background low-mass 
fragments produced due to collision induced dissociation (CID) in Tandem mass 
spectrometry (MS/MS). Tandem mass spectrometry (MS/MS fragmentation) also yields 
strong signature y- and b- ions without changing the charge state of any given peptide to 
allow more confident protein identification along with quantitation information [110, 
132]. This remains the case even for those tryptic peptides that are labeled at both the N 
termini and lysine side chains, and those peptides containing internal lysine residues due 
to incomplete cleavage with trypsin. The relative concentration of the peptides is thus 
deduced from the relative intensities of the corresponding reporter ions. In contrast to 
ICAT and similar mass-difference labeling strategies, quantitation is thus performed at 


















In a labeling approach like iTRAQ, identification of peptides and proteins from the CID 
spectrum is performed via comparison between the calculated fragments from peptide 
sequences in the database with observed peaks. From this comparison a score is 
calculated which reflects the statistical significance of the match between the spectrum 
and the sequences contained in a database [133]. The identified peptides are compiled 
into a protein „hit list‟, which is the output of a typical proteomic experiment as 
mentioned in the MS section earlier. Because protein identifications rely on matches with 
sequence databases, high-throughput proteomics is currently restricted largely to those 
species for which comprehensive sequence databases are available. 
 
Figure 1.11. Components of multiplexed isobaric tagging chemistry (Adopted from Ross, P.L. 
et al., [110] with permission) 
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1.3.11. Proteomics in colorectal cancer research- special emphasis on iTRAQ 
 Biomarkers are vital tools for the determination of cancer stages, disease progression and 
development of treatment strategies. In the last decade, biomarker discovery has 
progressed with a tremendous space, especially after sequencing of human genome as 
well as with the advancement of global high-throughput technologies. In the area of 
colorectal cancer research, mass spectrometry-based proteomics have resulted in 
significant advancement in the use of both gel-based and non-gel based (shotgun) 
techniques. In proteomics research on CRC, use of cell lines, tissue samples as well as 
animals as experimental models are quite common with cell lines having advantage of 
being homogeneous as well as easy to manage and characterize [5]. Different whole cell 
proteome, sub- proteomes (proteins obtained from sub-cellular fractionation) and serum 
(for secreted proteins) have been investigated using proteomics approaches that provides 
useful information regarding underlying molecular mechanism of the disease as well as 
identification of new therapeutic targets [134-141]. Examples of studying post- 
translational modification of proteins in order to provide information on alteration of 
signaling networks during CRC development are also available [142-145]. Over-
expression and suppression of several popular tumor related genes were performed in 
order to identify novel targets of these genes thereby opening new windows for CRC 
mechanism. For example, over-expression of the tumor suppressor TP53 in CRC cell 
lines were performed in order to investigate global proteome alteration due to p53 
induced apoptosis and revealed variation in expression levels of a large number of 
proteins involved in the cell cycle, reactive oxygen species (ROS) generation, organelle 
crosstalk, stress response and matrix metalloprotease (MMP) induction [146]. Similarly 
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global proteome alteration was studied upon Bax knock-down in CRC cells that revealed 
down-regulation of several interesting proteins such as VDAC1, VDAC2 (voltage 
dependent anion channel), 14-3-3 theta, MIF (Migration Inhibitory Factor), HSP70 etc 
[147]. Effect of RAS oncogene over-expression in CRC cells has showed the differences 
with the effects seen in non-colon cancer cell lines [148, 149].  Proteomics studies were 
also performed for the evaluation of mechanism of drug resistance in CRC. Proteomics 
study of 5-FU (5-fluorouracil) resistant colon cancer cells showed decreased levels of 
ATP synthase suggesting a possible role of ATP synthase for the development of 
resistance to this drug [150]. Proteome profiles of human CRC cell lines responsive or 
resistant to anti-EGFR (epidermal growth factor receptor) monoclonal antibody have also 
been reported [151]. However, only limited number of studies explored the area of CRC 
metastasis and most of the available literatures are based on the gel based proteomics 
approaches. Rho GDP- dissociation inhibitor alpha up-regulation was found to be 
associated with CRC metastasis as explored from a 2-DE comparison between metastatic 
versus non-metastatic CRC tissue samples [152].  Tropomyosin, annexin A5, IgE 
dependent histamine- releasing factor, GST (Glutathione S- transferase), transgelin 
variant and HSP 27 were some other proteins that were identified to be differentially 
expressed from this study [152]. Increased expression levels of HSP27, GST and annexin 
A2 and reduced levels of L-FABP (liver fatty acid-binding protein) were associated with 
the incidence of lymph node metastasis in CRC [153]. Until now only few limited studies 
in the area of CRC research [154-156] have exploited the high-throughput labeling 
technique, iTRAQ. Studies using 2-DE and 2D-DIGE followed by LC-MS/MS on in 
vitro CRC metastatic models, reported enhanced expression of triosephosphate 
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isomerase, α-enolase and HSP27 to be associated with increased incidence of lymph node 
metastasis from CRC [157, 158].  Label-free quantitative proteomics approaches [159] in 
recent years have reported trefoil factor 3 and growth/differentiation factor 15 as potential 
serum biomarkers for CRC metastasis. However, since no further downstream studies or 
bioinformatics analysis were associated with these reports, these studies did not lead to 
any substantial conclusion about the mechanisms involved in CRC metastasis. 
1.3.12. SW480 and SW620-cell line model used for this study 
SW480 and SW620, the colon cancer cell lines constitute a unique model for studying 
CRC disease progression. The SW480 cell line was derived from a Dukes' stage B colon 
carcinoma raised in a 50-year-old male patient and SW620 cell line was derived from one 
of the lymph node metastases raised in the same patient 6 months later [160] which 
confirms the isogeneity of these two cell lines. Their monoclonal origin is established by 
the presence of shared marker chromosomes seen on cytogenetic analysis [161]. The fact 
that these cell lines have a shared genetic background makes it easier to study the genetic 
basis of their phenotypic differences. Another advantage of studying these cell lines is 
that there is no possibility of drug-induced differences, since chemotherapy was not 
started until after the laparotomy for recurrent cancer (W. B. McCombs III, personal 
communication). Earlier studies established the higher metastatic potential of SW620 
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2.1. Summary  
With an aim to obtain more information and pick novel candidate biomarker(s) for 
colorectal cancer metastasis, we started with a discovery phase proteomics study and 
compared the whole cell proteome profiles of two isogenic colorectal cancer (CRC) cell 
lines (primary SW480 cell line and its lymph node metastatic variant SW620). This 
chapter describes the initial phase proteomics study that facilitated understanding about 
the molecular events as well as identified potential candidate biomarkers for CRC 
metastasis. Using iTRAQ
TM
 (isobaric tags for relative and absolute quantitation) based 
shotgun proteomics on in vitro metastatic model, we identified 1140 unique proteins, out 
of which 147 were found to be significantly altered in the metastatic cell. Ingenuity 
pathway analysis with those significantly altered proteins, revealed cellular organization 
and assembly as the top-ranked altered biological function. Differential expression 
pattern of 6 candidate proteins were validated by Western Blot analysis. Among these, 
the low expression level of β-catenin combined with the up-regulation of CacyBP 
(Calcyclin binding Protein), a β-catenin degrading protein, in the metastatic cell provided 
a rational guide for the downstream functional assays. The relative expression pattern of 
these two proteins was further validated in three other CRC cells by Western Blot and 
quantitative immunofluorescence studies. Over-expression of CacyBP in three different 
primary CRC cell lines showed significant reduction in adhesion characteristics as well as 
cellular β-catenin levels as confirmed by our experiments, indicating the possible 
involvement of CacyBP in CRC metastasis. In short, this study demonstrates successful 
application of quantitative proteomics approach to identify novel key players for CRC 
metastasis, which may serve as biomarkers and/or drug targets to improve CRC therapy. 
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2.2. Introduction  
Colorectal cancer (CRC) is the second most common cause of death among cancer 
patients in the developed world [163, 164] and the third-most common malignancy in 
USA [165, 166]. Although over the past decades modern surgical techniques and 
improved radio-chemotherapeutic regimens have increased survival rates, almost 50% of 
these patients eventually developed recurrent disease and metastasis leading to death 
within 5 years of diagnosis [167, 168]. Though the changes of vital proteins within a 
normal cell that leads to CRC has been extensively studied [5, 169, 170], the mechanisms 
that leads to metastasis is not yet fully understood. As a result most of the attempts to 
diagnose or treat the CRC metastasis have not been successful because they targeted only 
one or two proteins [171, 172] despite metastasis being caused by multiple factors. Hence 
at present, opting for a combination therapy targeting multiple proteins seems to be the 
most suitable alternative which calls for detailed understanding of the global proteomic 
alteration occurring within the cells. Acquisition of such voluminous information at a 
high degree of confidence is impossible by using traditional reductionist approaches in 
molecular biology thereby necessitating the successful implementation of strategies 
which can provide a vivid picture of global proteome alteration during different stages of 
cellular transformation processes [173]. 
Fortunately, the current advances in the fields of proteomics and bioinformatics provide 
the opportunity to study changes in global proteome level of cells at any given time point. 
Particularly, labeling approaches such as iTRAQ
TM
 (isobaric tags for relative and 
absolute quantitation) allows multiplexing of up to 8 samples to identify the relative 
abundance of proteins in different samples within a single liquid chromatography-mass 
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spectrometry (LC/ MS) based proteomics experiment [110, 174]. Unfortunately, till now 
only a few limited studies in the area of CRC research [154, 156, 175] have exploited this 
high-throughput technique which can provide results complementary to the traditional 
gel-based proteomics approaches such as two-dimensional gel electrophoresis (2DE) and 
two-dimensional difference gel electrophoresis (2D-DIGE) [111]. Earlier studies on in 
vitro CRC metastatic models using gel-based [157, 158] and label free quantitative 
proteomics approaches [159] have reported few significantly regulated proteins in 
metastasis and proposed HSP27, alpha enolase and triosephosphate isomerase as 
potential intracellular biomarkers and also trefoil factor 3 and growth/ differentiation 
factor 15 as serum biomarkers for CRC metastasis. However, since no further 
downstream studies or bioinformatics analysis were associated with these reports, these 
studies did not lead to any substantial conclusion about the mechanisms involved in CRC 
metastasis.  
To address this research gap, we present a thorough proteomics study of the lymph node 
metastasis of CRC by comparing the whole cell proteome profile of two isogenic 
(derived from same patient) CRC cell lines: the primary SW480 cell line and its lymph 
node metastatic variant SW620. The primary SW480 cell line was derived from a Dukes' 
stage B colon carcinoma obtained from a 50-year old male patient whereas the metastatic 
(SW620) variant was derived from the same patient after 1 year from the lymph node 
metastatic site [160]. Since the variation due to genetic background can be largely 
avoided for these two cell lines, they constitute a unique model for studying CRC 
progression and metastasis. A 4-plex iTRAQ workflow (Figure 1) involving 2D LC (2 
Dimensional Liquid Chromatography)-MS/MS (Tandem Mass Spectrometry) was 
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adopted for the identification of differentially expressed proteins. Taking into account the 
highly heterogeneous nature of CRC, it was anticipated that the list of differentially 
expressed proteins in this two cell line model will be able to represent at least some of the 
characteristics of clinical CRC and thereby serve as a useful reference for future research 
in the field of CRC progression. However, for better appreciation of our data, three other 
CRC cell lines of different metastatic potential were also included for functional 
validations of target proteins. The differential expression of β-catenin and Calcyclin 
binding protein (CacyBP) as reflected in five different CRC cell lines was an indication 
of the involvement of these two proteins in CRC metastasis. This was further reinforced 
by the roles of these two proteins in CRC metastasis during our functional investigations 
within this study. Over-expression of CacyBP in primary CRC cells caused reduction in 
cellular β-catenin level as well as adhesion characteristics of the cells. In summary, this 
study for the first time showed successful application of iTRAQ-based quantitative 
proteomics approach to provide glimpses of the pathophysiology as well as the discovery 
of novel biomarker/ drug targets for CRC metastasis.  
2.3. Materials and methods 
2.3.1. Reagents  
Unless otherwise indicated, all reagents used for the biochemical methods were 
purchased from Sigma-Aldrich. 
2.3.2. Cell culture  
Human colorectal cancer cell lines SW480, SW620, HT29, HCT116 and LoVo  were 
obtained from American Type Culture Collection (ATCC Numbers are CCL-228™, 
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CCL-227™, HTB-38™, CCL-247™ and CCL-229™ respectively). Among these, 
SW480, HCT116 and HT29 were primary CRC cell lines whereas SW620 and LoVo 
were derived from lymph node metastatic site. SW480 and SW620 cell lines were 
cultured in Dulbecco‟s Modified Eagle Medium with high glucose. HT29 and HCT116 
cells were cultured in McCoy's 5A whereas LoVo cell line was cultured in F-12K 
medium. All the media were supplemented with 10% fetal bovine serum (FBS) whereas 
DMEM and McCoy's 5A were additionally supplemented with 1% Pen-Strep 
(Streptomycin (10000 μg/ml) and Penicillin (10000 units/ml)). Cells were maintained at 
37⁰C in a humidified incubator supplemented with 5% CO2 until they were grown to 
80% confluences, washed two times in phosphate buffer saline (PBS) before harvesting 
and stored at -80⁰C  until further use. All the cells were allowed to undergo minimum 6-8 
passages and visually inspected to be healthy before harvesting. All supplements for cell 
culture were purchased from Gibco (Invitrogen). 
2.3.3. Pre-proteomic sample validation by flow cytometry  
SW480 and SW620 cells were cultured in parallel all the time. They were passaged 
usually after 48 hours of seeding when they reach about 80% confluence. Samples for 
proteomics analysis were prepared from cells harvested in healthy conditions containing 
cells from all stages of cell cycle. Cells were not synchronized at any particular stage of 
cell cycle. A flow cytometry analysis was done in order to validate the cells before 
proteomics analysis. To asses percentage of cells in different stages of cell cycle, 
adherent SW480 and SW620 cells were trypsinized, washed 2 times in cold PBS and 
stained with propidium iodide staining solution as per the manufacturers‟ protocol (FITC 
Annexin V Apoptosis Detection Kit I, BD Pharmingen™).  
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2.3.4. Proteomics Sample preparation  
Samples were prepared by heating harvested cells at 100⁰C for 10 minutes with a lysis 
buffer containing 0.5 M triethylammonium bicarbonate (TEAB), pH 8.5 and 1% SDS 
with intermediate vortexing. The lysate was centrifuged at 12,500 g for 1 hour at 15⁰C 
and the supernatant was stored at -80⁰C until further use. Protein quantitation was 
performed using RCDC Protein Assay Kit (Bio-Rad). 100 µg of each sample was used 
for iTRAQ labeling.  
2.3.5. iTRAQ labeling  
iTRAQ labeling was carried out using iTRAQ
TM
 Reagent 4-Plex kit (AB SCIEX) based 
on the manufacturer‟s protocol with minor modifications. A pair of SW480 and SW620 
whole cell lysates were labeled with iTRAQ labeling reagent 114 and 115 respectively 
and likewise another pair of biological replicates of the same samples (whole cell lysate 
from another batch of culture of these two cell lines) were labeled with 116 and 117 
iTRAQ labeling reagents respectively. Briefly, the cell lysates were reduced with tris-(2-
carboxyethyl) phosphine (TCEP), alkylated with methyl methane-thiosulfonate (MMTS) 
and diluted 20 times before digesting with trypsin (w/CaCl2; Promega) with a trypsin to 
protein ratio of 1:10 (w/w) at 37⁰C for 16 hours. The digested peptides were then dried 
and reconstituted with 0.5 M TEAB. The dried peptides were then labeled with respective 
isobaric tags, incubated at room temperature for 2 hours before being combined. The 





2.3.6. Strong cation exchange (SCX) chromatography  
In order to remove all interfering substances such as dissolution buffer, organic solvent 
like ethanol, acetonitrile, reducing agent (TCEP), alkylating agent (MMTS), SDS, 
calcium chloride and excess iTRAQ
TM
 reagents etc., strong cation exchange 
chromatography was carried out for the combined iTRAQ-labeled peptides using the 
cation exchange system provided in the iTRAQ Method Development Kit (AB SCIEX). 
The eluted fraction was desalted using Sep-Pak C18 cartridges (WATERS), dried and 
Figure 2.1. Schematic representation of the experimental design for iTRAQ labeling 
showing biological replicates from primary and metastatic CRC cells. Two biological 
replicates from SW480 cell were labeled with 114 and 116 respectively, and from SW620 were 
labeled with 115 and 117 respectively. 
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then reconstituted with 50 µl of 5 mM KH2PO4, 5% acetonitrile at pH 3 for 2D LC-
MS/MS analysis.  
2.3.7. 2D LC analysis  
Peptide separation was performed on an Ultimate™ 3000 liquid chromatography system 
(Dionex-LC Packings) equipped with a Probot™ MALDI spotting device. 48 µl (via 
multiple injections) of the labeled peptides was injected by microliter-pickup injection 
mode into a 0.5 × 23.5 mm SCX NanoEase™ trap column (WATERS) for first 
dimensional separation. The SCX buffers A and B were 5 mM KH2PO4 buffer, pH 3, 5% 
ACN and 5 mM KH2PO4 buffer, pH 3, 5% ACN with 100 mM KCl respectively. The 
flow rate was 6 μl/ minute. Six fractions were obtained using step gradients of SCX 
buffer B: unbound, 0-2, 2-10, 10-20, 20-30 and 30-100%. The eluting fractions were 
captured alternatively onto two 0.18 × 23.5 mm Symmetry 300™ C18 NanoEase™ trap 
columns (WATERS) and washed with 0.05% TFA followed by gradient elution and 
separation with a 300 µm × 150 mm Symmetry C18 NanoEase™ reversed phase (RP) 
column (C18 SYMMETRY 300
TM
; WATERS). Mobile phases A and B used for second-
dimensional separation were 2% ACN with 0.05% TFA and 80% ACN with 0.04% TFA, 
respectively. Similar parameters were used in our previous studies as well [176, 177]. 
LC fractions eluted from the RP column were then mixed directly with MALDI matrix 
solution (7 mg/ml α-cyano-4-hydroxycinnamic acid (CHCA) and 130 μg/ml ammonium 
citrate in 75% ACN) at a flow rate of 5.4 μl/ minute via a 25 nl mixing tee before they 
were spotted in 28 × 44 spot arrays on 123 × 81 mm Opti-TOF™ LC/MALDI Inserts 
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(AB SCIEX) using a Probot Micro Precision Fraction collector (Dionex-LC Packings), at 
a frequency of one spot per 5 seconds. 
2.3.8. Tandem mass spectrometric analysis (MALDI-TOF/ TOF)  
MS and MS/MS analyses were performed on a 4800 MALDI-TOF/TOF Analyzer (AB 
SCIEX) operating in MS-positive reflector mode. Laser intensity was set to 4000 for MS 
and 4300 for MS/MS acquisition. For MS, 1000 shots were accumulated in each spot and 
MS spectra were acquired between m/z 920-3900.  Up to 7 precursor ions with the 
highest peak intensity of each spot with signal to noise ratio (S/N) of at least 50 were 
automatically selected for MS/MS acquisition. MS/MS was performed using nitrogen 
(N2) as the collision gas at collision energy of 2 kV and collision gas pressure of ~1 × 10
-
6
 Torr, with an accumulation range of 2000-5000 shots (stop conditions applied to 
individual MS spectrum when minimum 10 peaks reach estimated S/N of 75 ) for each 
spectrum.  
2.3.9. Peptide and protein identification  
Protein identification and relative iTRAQ quantification were performed with 
ProteinPilot™ Software 2.0.1 (AB SCIEX) using the Paragon™ algorithm for the peptide 
identification which was further processed by Pro Group
TM
 algorithm where isoform-
specific quantification was adopted to trace the differences between expressions of 
various isoforms. User defined search parameters were as follows: (i) Sample Type: 
iTRAQ 4plex (Peptide Labeled); (ii) Cysteine alkylation: MMTS; (iii) Digestion: 
Trypsin; (iv) Instrument: 4800; (v) Special factors: None; (vi) Species: None; (vii) ID 
Focus: Biological modifications, (viii) Database: IPI_HUMAN_3.68_tdx.fasta (released 
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in December 2009, 174110 proteins searched: including 87055 entry and equal number of 
randomized sequences) (ix) Search effort: Thorough. For iTRAQ quantitation, the 
peptide for quantification was automatically selected by Pro Group
TM
 algorithm to 
calculate the reporter peak area, error factor (EF) and p value. The resulting dataset was 
auto bias-corrected to get rid of any variations imparted due to the unequal mixing during 
the combination of different labeled samples.  
The identified proteins were grouped by the ProGroup algorithm in the software to 
minimize redundancy. A decoy database search strategy was adopted to estimate the false 
discovery rate (FDR) for peptide identification. A corresponding randomized database 
was generated using the Proteomics System Performance Evaluation Pipeline (PSPEP) 
feature in the ProteinPilot™ Software 2.0.1. For this study, a strict unused confidence 
cutoff >1.3 was used as the qualification criteria, which corresponds to a peptide 
confidence level of 95%. With this filter, the corresponding false discovery rate (FDR= 
1.3758%) was calculated from the decoy hits. The results were then exported into 
Microsoft Excel for manual data interpretation. Subsequently, the meaningful cut-off for 
up-regulation (≥ 1.5) and down-regulation (≤ 0.67) of proteins was finalized  by the use 
of biological replicate method proposed by Gan et al [178]. 
2.3.10. Bioinformatics analysis (Gene ontology study)  
To better appreciate the data set generated, protein list of 147 significantly altered 
proteins was uploaded into Ingenuity Pathway Analysis (IPA) software server 
(http://www.ingenuity.com) and analyzed using the Core Analysis module to rank the 
proteins into top biological functions including disease and disorders as well as molecular 
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and cellular functions. The reference set and parameters for Ingenuity Pathway Analysis 
(IPA) on significantly altered protein list was as follows: i) Reference set: Ingenuity 
Knowledge Base (Genes Only), ii) Relationship to include: Direct and Indirect, iii) 
Filter Summary: Consider only molecules and/or relationships where (species = 
Human) AND (cell lines = All Cancer cell lines in ingenuity database). 
Additionally, to confirm the quality of sample preparation, the whole dataset including all 
identified proteins was analyzed for the random distribution of protein candidates in 
different cellular compartments.  
2.3.11. Validation of proteomics identification results using western blot  
Equal amount of protein samples extracted from harvested cells (from both biological 
replicates used for i-TRAQ; CacyBP overexpressed and control cells etc.) were resolved 
by 1-D SDS-PAGE. Upon completion of electrophoresis, the proteins were electroblotted 
onto PVDF (Polyvinylidene fluoride) membranes (Bio-Rad). The blots were then blocked 
using 5% (w/v) nonfat dry milk in PBS with 0.1% Tween 20 (PBS-T) overnight prior to 
immunoprobing with antibodies diluted in PBS-T with 1% (w/v) milk for 2 hours each. 
The membranes were incubated with mouse anti-Annexin A2 (1:1500), mouse anti-Villin 
(1:1000), mouse anti-β catenin (1:1000), mouse anti-MARCKS (1:2000) and mouse anti-
CacyBP (1:5000) from Santa Cruz Biotechnology, Inc. as well as rabbit anti-Stathmin 
(1:500) from Cell Signaling Technology and mouse anti-actin (1:4000) from BD 
Transduction Laboratories™. HRP-conjugated anti-mouse IgG (1:5,000) from GE 
Healthcare, or HRP-conjugated anti-rabbit IgM (1:5,000) from Pierce Biotechnology 
were used as secondary antibodies and incubation period was 2 hours. Three washes in 
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PBS-T were carried out between each antibody incubation step. Subsequent visualization 
was performed using ECL substrate (Santa Cruz Biotechnology, Inc.) with actin levels as 
the loading control. 
2.3.12. Reverse transcription polymerase chain reaction (RT-PCR)  
Total RNA was isolated using TRIzol® reagent (Invitrogen) according to the 
manufacturer‟s protocol and quantified with Nanovue (GE Healthcare). Specific primers 
for CacyBP were designed using primer-BLAST software (Supplementary Table 1). β-
actin was used as internal control to check the efficiency of cDNA synthesis and PCR 
amplification. 5 µg of RNA was used for cDNA synthesis and amplified using primers 
for CacyBP and β-actin. PCR products were separated by 2% agarose gel electrophoresis 
for visual identification. 
2.3.13. Cloning CacyBP (Calcyclin binding protein) gene into pXJ40 vector  
Full-length cDNA encoding human CacyBP/SIP was generated from CRC SW620 cells 
by RT-PCR. The specific primers for CacyBP/SIP were 
5‟CCGCTCGAGATGGCTTCAGAAGAGCTA 3‟ (sense) and 
5‟AACTGCAGTCAAAATTCCGTGTCTCCTTTG 3‟ (antisense) [179]. The PCR 
product was cloned into pXJ40 vector by restriction digestion at XhoI and PstI sites 
followed by ligation reaction using T4 DNA ligase (New England Biolabs) in order to 
achieve the sense vector, pXJ40-CacyBP. 
2.3.14. Cell transfection  
Cells were plated and grown to 70% to 90% confluency without antibiotics. 
Transfections were done with Lipofectamine
TM
 2000 (Invitrogen), as directed by the 
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manufacturer. The CacyBP sense vector (pXJ40-CacyBP) was introduced into SW480, 
HCT116 and HT29 cells. Transfection was allowed for 24 hours before harvesting or 
using the cells for any experiment. SW480 cells transfected with CacyBP and empty 
vector pXJ40, will be addressed as SW480-CacyBP and SW480-pXJ40 respectively. 
Similar addresses are applicable for HCT116 and HT29 cells as well. 
2.3.15. Immunofluorescence staining  
The cells (wild type SW480 and SW620, SW480-pXJ40 and SW480-CacyBP) were 
plated onto cleaned-up coverslips and grown until 60% confluency. They were washed 
with PBSCM (PBS with 1mM Ca
2+
 and 1mM Mg
2+
) and fixed with 3% 
Paraformaldehyde for not more than 30 minutes at room temperature. The coverslips 
were washed with PBSCM and permeabilized for 15 minutes with 0.1% saponin in 
PBSCM. The cells were incubated with mouse monoclonal anti-CacyBP antibody (Santa 
Cruz Biotechnology; diluted 1:2000 in 1% BSA with PBSCM) and rabbit monoclonal 
anti–β-catenin antibody (abcam; diluted 1:250 in 1% BSA with PBSCM) after blocking 
with 3% BSA for 1 hour. The cells were then incubated with Alexa Fluor-488 conjugated 
goat anti-mouse IgG (Invitrogen) and Alexa Fluor-594 conjugated goat anti-rabbit IgG 
(Invitrogen) at 1:200 dilutions for 1 hour each and mounted on glass slides with DAPI 
mounting solution (Santa Cruz Biotechnology). The immunofluorescence was analyzed 
under Carl Zeiss LSM 510 Meta. 
2.3.16. Adhesion assay  
Adhesion assay was performed as mentioned by Murphy et al [180] with certain 
modifications. Briefly, precoating of 96 well plate was performed with 10 µg/ml of 
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fibronectin (Sigma) in PBS at 37⁰C for 1 hour. The wells were blocked with 0.5% BSA 
in culture medium and 0.1% BSA in medium was used as the washing buffer. CacyBP 
overexpressed SW480, HCT116 and HT29 along with their corresponding contol cells 
(transfected with empty pXJ40 vector) were seeded as 20×10
3
 per well of the 96 well 
plate. Images for bright field of cells after adhesion were taken using a digital compact 
camera (Olympus, C-7070) attached to the microscope. Absorbance was measured at 550 
nm after lysing with 2% SDS. 
2.3.17. Statistical analysis  
Statistical analyses were conducted with GraphPad Prism 5 software. The differences in 
immunofluorescence staining between SW480 and SW620 cells, SW480-pXJ40 and 
SW480-CacyBP were estimated using paired t test. The significant difference between 
adhesion characteristics between empty vector and CacyBP overexpressed cells 
(SW480, HCT116 and HT29) were also estimated using paired t test. P value less than 
0.05 was considered as statistically significant for each cases. 
2.4. Results 
2.4.1. Pre-proteomic validation of SW480 and SW620 cell lines  
No significant differences were seen between SW480 and SW620 on cell cycle analysis 
of cells growing in DMEM containing 10% FBS and 1% pen-strep. For SW480, the 
ratios of G1: S: G2 were 28%:57%:3.4% compared with 28.9%:56.7%:3.5% for SW620 
(Supplementary figure 2.1, appendix). An earlier study on validation of these two cell 
lines as a model of colon cancer progression, also reported similar observations [162].   
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2.4.2. iTRAQ proteomics profiling of SW480 and SW620 cell lines 
To understand the global proteomic alteration in CRC metastasis, protein extracts from 
the primary SW480 cells and lymph node metastatic SW620 cells were analyzed using 
iTRAQ approach (Figure 2.1.). Two biological replicates for each cell line were 
compared for analysis of dataset as well as to measure the variation caused by random 
biological effects. 
A strict cut-off for unused protein score ≥ 1.3 was used as the first qualification criterion 
which corresponds to a 1.3758% false discovery rate. With this filter, the iTRAQ 
experiment identified total 1140 proteins (Supplementary table 2.1., appendix soft copy). 
Out of these, more than 50% proteins correspond to ≥4 peptide match. The quality of 
sample preparation can be inferred from the random distribution of the proteins 
throughout the cellular compartments. Ingenuity pathway analysis study with all 1140 
identified proteins showed that there were about 50% of proteins from the cytoplasm, 
33% from the nucleus, 7% from plasma membrane and 2% from extracellular space 






Figure 2.2. Cellular distribution of all the proteins identified in both 
biological replicates from the iTRAQ experiment. The quality of protein 





Subsequently the final cut-off ratio for up- or down-regulation of proteins was 
determined using biological replicate method [178] since biological variation has the 
highest variation with lower number of proteins covered when compared to technical or 
experimental replicates. Hence, fixing a cut-off with the biological variation enhances the 
certainty that the observed protein alteration is real and thereby eliminates the need for 
other types of replicates [178]. Applying this method to our dataset, we observed about 
48% variation corresponding to 88% coverage of data (Figure 2.3.A), which is in close 
conformity with the findings by Gan et al. Based on this, the cut-off was fixed at 1.5 fold 
(±50% variation) corresponding to the iTRAQ ratio of >1.5 for up-regulation and <0.67 
for down-regulation. 
Applying these cut-off thresholds to the two sets of biological replicates individually and 
considering only common proteins which passed the criteria in both replicates, we 
identified a total of 147 proteins to be significantly altered. Out of these, 94 (64%) were 
down-regulated and 53 (36%) were up-regulated. Less than 22% of these proteins 
correspond to a single peptide match. To support the certainty of the protein match, 
validation of two proteins (MARCKS and Villin) that correspond to a single peptide 
match was done by western blot study (Figure 2.5.A). 
The corresponding ratios of these significantly altered proteins (147 proteins) were 
plotted to calculate the correlation between two replicates (R
2
 = 0.85; Figure 2.3.B). 
Replicate 1 corresponds to SW620/SW480 from passage 22 (115/114) and replicate 2 
corresponds to SW620/SW480 from passage 24 (117/116). More than 78% of these 
proteins were significantly altered in the peptide level (p value <0.05) [181] as assigned 
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by the protein pilot software. This indicates a measurement of the confidence of true 





2.4.3. Gene ontology study for the significantly altered proteins  
Gene Ontology studies using Ingenuity Pathway Analysis software classified the 
significantly altered proteins as per their molecular function (Figure 2.4.A) as 
well as rank them as per the biological functions. Interestingly, the top-ranked 
biological function was cellular organization and assembly (Figure 2.4.B; 
Supplementary figure 2.2., appendix) which is consistent with the biological topic 
(metastasis) of this study.  
 
Figure 2.3. A) Determination of experimental variation using 1140 common proteins (False Discovery 
rate < 5%) identified in both biological replicates: The horizontal axis represents % variation between 
iTRAQ ratios of same protein from different biological replicates. The primary vertical axis represents the 
corresponding number of proteins (bars) having different % variation. The secondary vertical axis represents 
the cumulative % of the counted proteins (lines) where 100% equals to 1140 proteins. More than 88% of the 
proteins had less than 50% of variation due to random biological effects justifying the true regulation cut-off 
at 1.5 fold. B) Correlation between the iTRAQ ratios of finally screened 147 proteins from both 
biological replicates. Plotting the iTRAQ ratios of the finally screened 147 proteins from both biological 
replicates identified the correlation coefficient (R
2
) at 0.85, which interpreted acceptable variation of iTRAQ 







2.4.4. Relevance of iTRAQ dataset proteins to the process of CRC metastasis  
The significantly altered proteins from the iTRAQ experiment were functionally analyzed 
and classified to interpret the molecular events relevant to the pathophysiology of CRC 
metastasis. Proteins from different classes are described below, for their possible 
contribution to the molecular mechanism behind CRC metastasis. 
 Proteins related to Cytoskeletal signaling: All the cytoskeletal signal related proteins 
such as the intermediate filament, actin filament and microtubule associated proteins 
help to maintain the integrity of a cell and also between cells. 
Figure 2.4. Ingenuity Pathway Analysis for significantly altered proteins in metastatic versus 
primary CRC: A) Classification of significantly regulated proteins as per their molecular functions 
using Ingenuity Pathway Analysis. B) Top functional networks to which the significantly altered 
proteins are associated with (Diagram redrawn based on original IPA output file shown in 
supplementary figure 3): Cellular assembly and organization is the top ranked one and was highlighted-
Gene Ontology done by IPA analysis. 
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Our study identified different proteins belonging to the intermediate filament family 
to be significantly down-regulated in the metastatic cell line (Table 2.1.). These 
include Isoform 3 of Keratin, type I cytoskeletal 13, Keratin, type I cytoskeletal 23, 
Keratin, type II cytoskeletal 5 from cytoplasm and Lamin-A/C [182] from nucleus. 
Plectin and plectin binding protein Nesprin 3 were also down-regulated in the 
metastatic cell. 
Tubulin-β 2A and 2B chains (Table 2.1.) were down-regulated whereas stathmin was 
up-regulated in the metastatic cell. The differential expression pattern of stathmin was 
validated by western blot (Figure 2.5.A). Isoform 2 of clathrin heavy chain 1 was 
down-regulated as well. 
Actin and several actin binding proteins such as actinin-α 1, actinin-α 4, COTL1 
(Coactosin-like protein) were found to be down-regulated in the metastatic SW620 
cell (Table 2.1.). Additionally, PDLIM4 (Isoform 1 of PDZ and LIM domain protein 
4), LASP1 (Isoform 1 of LIM and SH3 domain protein 1) and LIMA1 (LIM domain 
and actin binding 1 isoform a) were down-regulated in the metastatic cell as well. 
Villin, an unusually versatile actin modifying protein [183], myosin 10 and  
MARCKS (Myristoylated alanine-rich C-kinase substrate), an F-actin crosslinking 
protein [184] were found to be up-regulated in the metastatic cell line. The 
differential expression pattern of Villin and MARCKS were validated by western blot 




























Intermediate filament associated proteins 
42.14 44.4 IPI00009867.3 
Keratin, type II 
cytoskeletal 5  
0.1577 0.1567 ↓ 
13.35 44.8 IPI00304458.2 
Keratin, type I 
cytoskeletal 23  
0.1532 0.1557 ↓ 
6.83 26.2 IPI00171196.2 
Isoform 3 of 
Keratin, type I 
cytoskeletal 13  
0.2196 0.1276 ↓ 
2 50.7 IPI00930614.1 
KRT13 protein 
(Fragment)  
0.0652 0.0339 ↓ 
49.17 46.5 IPI00216953.1 
Isoform ADelta10 
of Lamin-A/C  
0.6152 0.539 ↓ 
67.47 21.6 IPI00398778.3 
Isoform 6 of Plectin-
1  
0.5458 0.586 ↓ 
2 6.4 IPI00830100.1 
Isoform 3 of 
Nesprin-3  
0.6195 0.5905 ↓ 
Microtubules associated proteins 
2 34.4 IPI00013475.1 
Tubulin beta-2A 
chain  
0.2563 0.3601 ↓ 
4 34.4 IPI00031370.3 
Tubulin beta-2B 
chain  
0.3066 0.4354 ↓ 
6.61 5.9 IPI00455383.4 
Isoform 2 of 
Clathrin heavy chain 
1  
0.5648 0.5212 ↓ 
8.08 36.2 IPI00479997.4 Stathmin  1.7415 2.3801 ↑ 
Actin filament associated proteins 
61.33 25.4 IPI00644576.1 Filamin A, alpha  0.6238 0.464 ↓ 
55.16 44 IPI00013808.1 Alpha-actinin-4  0.307 0.2517 ↓ 
30.43 16 IPI00943563.1 Filamin B isoform 4  0.4525 0.3409 ↓ 
21.57 32.2 IPI00759776.1 
Actinin, alpha 1 
isoform a  
0.4804 0.4413 ↓ 
14.02 14.2 IPI00883896.1 
LIM domain and 
actin binding 1 
isoform a  
0.6254 0.6506 ↓ 
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6.42 12.2 IPI00646182.5 
Na+/K+ -ATPase 
alpha 1 subunit 
isoform c  
0.5893 0.5923 ↓ 
6.3 26.8 IPI00000861.1 
Isoform 1 of LIM 
and SH3 domain 
protein 1  
0.5497 0.5373 ↓ 
6.13 10 IPI00294578.1 





0.0939 0.1039 ↓ 




0.3855 0.3136 ↓ 
4.01 5.9 IPI00026216.4 
Puromycin-sensitive 
aminopeptidase  
0.4925 0.5115 ↓ 
4 5.9 IPI00894514.1 
Rho-associated 
protein kinase 2  
0.358 0.405 ↓ 
4 8.8 IPI00910593.1 Calponin-2  0.5658 0.6297 ↓ 
2.82 5.4 IPI00946636.1 
Putative 
uncharacterized 
protein ATP6V1A  
0.498 0.5727 ↓ 
2.54 3.6 IPI00329719.1 Myosin-Id  0.3573 0.2354 ↓ 
2 2.4 IPI00032206.2 
Isoform 1 of PDZ 
and LIM domain 
protein 4  
0.1322 0.091 ↓ 
2 5.6 IPI00017704.3 
Coactosin-like 
protein  
0.3394 0.4408 ↓ 
1.74 13.5 IPI00878066.1 
Ras-related C3 
botulinum toxin 
substrate 2  
0.4497 0.5653 ↓ 
15.52 48.6 IPI00815642.1 
TMSB4X protein 
(Fragment)  
4.1195 4.0776 ↑ 
12.16 15.8 IPI00409590.1 
Isoform 1 of LIM 
domain only protein 
7  
3.1636 2.473 ↑ 
6.16 14.8 IPI00790503.3 
Isoform 3 of 
Myosin-10  
1.7212 2.1335 ↑ 
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3.06 32.8 IPI00456008.1 
ATP synthase, H+ 
transporting, 
mitochondrial F0 
complex, subunit F6 
isoform b precursor  
1.5493 1.5883 ↑ 
2.8 10.7 IPI00385042.4 
Nucleolar GTP-
binding protein 1  
1.5569 1.5557 ↑ 
2 3 IPI00218852.4 Villin-1  2.4137 2.6104 ↑ 
2 3.3 IPI00219301.7 
Myristoylated 
alanine-rich C-
kinase substrate  
2.0767 1.7886 ↑ 
 
a
 The list contains quantitative information about the significantly altered proteins related 
to cytoskeletal signaling from the two biological replicates of the iTRAQ experiment. 
These proteins have met the criteria (i.e. unused protein score > 1.3 and change in 
expression level of at least 1.5 fold for metastatic vs. primary cell) as defined in the 
“materials and method” as well as “results” section. 
 
 Proteins related to cellular adhesion:  
Cellular adhesion molecules such as β-catenin, L1CAM (Isoform 1 of Neural cell 
adhesion molecule L1), NAPG (γ-soluble NSF attachment protein) and NCAM1 were 
down-regulated (Table 2.2.). Also a β-catenin degrading protein, CacyBP (Isoform 1 
of Calcyclin-binding protein) [185] was found to be up-regulated in the metastatic 
cell. This can be an indication of higher degradation rate of β-catenin in the metastatic 
cell resulting in ultimate lowering of its protein level. The expression patterns of β-
catenin and CacyBP was hence validated by western blot. Since β-catenin is 
associated with cellular adhesion [186, 187], it can be an indication of any molecular 
phenomenon that causes cells to become loosen from each other, ultimately leading to 
migration. Adhesion assay performed with same number of cells from both primary 
and metastatic type, also showed lack of adhesion for the metastatic cell line 
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(Supplementary figure 2.3., appendix), which supports the above hypothesis. Hence 
we focused on β-catenin and the β-catenin degrading protein CacyBP as interesting 
candidate proteins associated with CRC metastasis and thereby performed additional 
validation for them in a larger panel of CRC cells and validation of CacyBP in the 
RNA level (See below; Detailed explanations in discussion part).    
 Proteins regulating cell migration:  
Annexin A2, found to inhibit cell migration in vitro [188] was down-regulated in the 
iTRAQ experiment on the metastatic cell. This observation interprets an increase in 
cell migration of the metastatic cells and it was validated by western blot analysis 
(Figure 2.5.A). HMGB3 (High mobility group protein B3) [189] was up-regulated in 
this study (Table 2.2.), which might be an indication of enhanced cell migration as 
well. 
Table 2.2. Functional classification of the significantly altered proteins related to tight 





















Proteins related to cellular adhesion 
2.33 8.5 IPI00219893.6 β-catenin  0.4332 0.3983 ↓ 
2 5.8 IPI00902968.1 
Putative 
uncharacterized 
protein NCAM1  
0.3819 0.3367 ↓ 




0.4782 0.4095 ↓ 
1.32 8 IPI00871467.2 




0.5547 0.5623 ↓ 
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6.01 21.1 IPI00395627.3 
Isoform 1 of 
Calcyclin-binding 
protein  
1.5097 1.5154 ↑ 
Proteins regulating cell migration 
30.09 54.3 IPI00455315.4 
Isoform 1 of 
Annexin A2  
0.3126 0.3162 ↓ 
20.01 52 IPI00217477.5 
High mobility 
group protein B3  
2.056 1.8776 ↑ 
4 5.3 IPI00908762.2 
Galectin-3-binding 
protein  
3.2509 2.236 ↑ 
 
a
 The list contains quantitative information about the significantly altered proteins related 
to tight junction signaling from the two biological replicates of the iTRAQ experiment. 
These proteins have met the criteria (i.e. unused protein score > 1.3 and change in 
expression level of at least 1.5 fold for metastatic vs. primary cell) as defined in the 
“materials and method” as well as “results” section. 
 
 Proteins involved in cell death:  
Meredith and Frisch were the first to show that normal endothelial and epithelial cells 
actively trigger an apoptotic response called anoikis (cell death induced by 
inappropriate or loss of cell adhesion) once they lose their cell–cell and cell–matrix 
interactions or if the adhesive substrate is inadequate [190-192]. Anoikis suppression, 
therefore, is likely to be a prerequisite for tumor cells to be successfully metastasized 
to the distant sites [193, 194]. Our study identified proteins from different classes 
(Table 2.3.) which are either in favor of or against apoptosis.  
A decreased expression level of chaperones and heat shock proteins such as HSP90α 
and HSPH1 was observed in the metastatic cell. Since these proteins play an 
indispensible role in defense against cellular stress [195], their down- regulation 
might reflect triggering of anoikis during metastasis. 
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Ubiquitination-Proteasome Pathway related proteins like PSMC1 or 26S protease 
regulatory subunit 4, PSMD2 or 26S proteasome non-ATPase regulatory subunit 2, 
PSMD6 22 kDa protein, SQSTM1 or Isoform 1 of Sequestosome-1 were identified to 
be down-regulated in the metastatic cell line. Degradation of proteins via the 
ATP/ubiquitin-dependent pathway mediates apoptosis [196]. Therefore down-
regulation of these proteasomal proteins represents a defense mechanism against 
degradation of proteins resulting in inhibition of apoptosis (precisely anoikis). This 
can be one of the probable defense mechanisms against the depletion of chaperon-
heat shock proteins, preventing apoptosis as well as leading to successful metastasis.  
Decreased expression of certain oxidative stress related proteins such as TRIM29 
Isoform β of Tripartite motif-containing protein 29, OXR1 Isoform 1 of Oxidation 
resistance protein 1, CD9 15 kDa protein and GOLM1 Isoform 1 of Golgi membrane 
protein 1 [197] illustrated that anoikis has been triggered in the metastatic cell due to 
inappropriate or lack of adhesion. At the same time some other antioxidant proteins 
such as peroxiredoxin 3 and peroxiredoxin 5 were found to be up-regulated. This 
indicated two antagonizing networks (supporting and opposing anoikis) working 





























Chaperones and heat shock proteins 
47.49 39.7 IPI00382470.3 




0.6532 0.6621 ↓ 
13.6 20 IPI00939163.1 
Isoform Alpha 
of Heat shock 
protein 105 
kDa  
0.5197 0.4833 ↓ 





0.4231 0.5396 ↓ 
3.3 10.1 IPI00006713.1 
DnaJ homolog 
subfamily C 
member 3  
1.6835 1.6057 ↑ 
Proteasome ubiquitination related proteins 
6.76 17 IPI00011126.6 
26S protease 
regulatory 
subunit 4  
0.6386 0.4487 ↓ 





subunit 2  
0.5263 0.4718 ↓ 
4 13 IPI00179473.9 
Isoform 1 of 
Sequestosome-
1  
0.5146 0.3127 ↓ 
Defense related Proteins   
3.95 13 IPI00232492.4 




protein 29  
0.3258 0.4698 ↓ 
2 2.4 IPI00942506.1 
Isoform 1 of 
Oxidation 
resistance 
protein 1  
0.595 0.353 ↓ 
2 7.5 IPI00795937.1 
CD9 15 kDa 
protein  
0.3824 0.6226 ↓ 
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2 10.5 IPI00936772.1 
Isoform 1 of 
Golgi 
membrane 
protein 1  
0.5964 0.6545 ↓ 
8 18.1 IPI00374151.1 
peroxiredoxin 3 
isoform b  
1.6906 1.8286 ↑ 




1.5337 1.9896 ↑ 
Other apoptosis related proteins   





0.2373 0.2472 ↓ 




member 16  
0.3846 0.2272 ↓ 
 
a
 The list contains quantitative information about the significantly altered proteins related 
to apoptosis from the two biological replicates of the iTRAQ experiment. These proteins 
have met the criteria (i.e. unused protein score > 1.3 and change in expression level of at 
least 1.5 fold for metastatic vs. primary cell) as defined in the “materials and method” as 
well as “results” section. 
 
2.4.5. Validation of iTRAQ data on selected candidates 
Totally 6 candidate proteins were validated using western blot studies. Annexin A2 and 
β-catenin were found to be down-regulated whereas stathmin, Villin, MARCKS and 
CacyBP were up-regulated in the metastatic SW620 cell line (Figure 2.5.A). This result 
verified similar differential expression pattern as the iTRAQ results.  Out of these 6 
candidate proteins, villin and MARCKS were actin polymerization associated proteins 
[183, 184], stathmin was a microtubule dynamics regulatory  protein [198, 199] and 
Annexin A2 was a cell migration inhibitory protein [188]. β-catenin was related to 
cellular adhesion [186, 187] and was known to degrade by several pathways one of which 
involves CacyBP [185]. CacyBP was chosen for further analysis in order to provide 
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original and new insights into CRC metastasis since it was not been previously reported 
to be differentially expressed in CRC metastasis compared to the primary tumor. Since 
reduction of β-catenin level is correlated with increase in CacyBP expression level in our 
study, both CacyBP and corresponding cellular β-catenin levels were validated in several 
other CRC cell lines of different metastatic potential. HT29, HCT116 and SW480 were 
included as primary cells whereas SW620 and LoVo were included as lymph node 
metastatic cells. CacyBP was found to be up-regulated in SW620 and LoVo cells whereas 
β-catenin was found to be down-regulated in those cell lines compared to other primary 
cells (Figure 2.5.B). 
Additional validation for CacyBP was done by RT-PCR in order to confirm the 
expression in the mRNA level. Using specific primers for the RT-PCR the increased 
mRNA expression level of CacyBP was observed in the metastatic SW620 cell, (Figure 
2.5.C) which is in conformity with the proteomics as well as the western blot results. β-






2.4.6. Quantitative validation of CacyBP and β-catenin by immunocytochemistry  
Immunofluorescence analysis for CacyBP and β-catenin protein expression levels in 
SW480 and SW620 cells showed up- regulation of CacyBP (shown in green) and down- 
regulation of β-catenin (shown in red) in SW620 cells compared to SW480 (Figure 2.6.). 
46 pairs of cells were considered for the quantitative analysis (fluorescent intensity: area) 
and SW480 vs SW620 groups were analyzed for significant variation between green as 
well as red channels using paired t test. For both CacyBP and β-catenin stainings, the p 
Figure 2.5. Validation of proteomics (whole cell proteome from primary and metastatic CRC cells) 
results A) Western-blot studies to validate differential expression pattern of 6 candidate proteins: Up-
regulation of villin, MARCKS, CacyBP and stathmin and down-regulation of annexin A2 and β-catenin in 
SW620 cell line were observed by western blot studies which were in conformity with the iTRAQ results. 
B) Validation of CacyBP and β-catenin expression level in HT29, HCT116, SW480, SW620 and LoVo 
cells. Actin was used as a loading control. C) Validation of CacyBP at the mRNA level using RT-PCR: 
CacyBP was found to be significantly up-regulated in the mRNA level from SW620 cell. β-actin was used 









2.4.7. Over-expression of CacyBP in primary colon cancer cell lines showed 
decreased cellular β-catenin level as well as significant reduction in cellular adhesion  
Over-expression of CacyBP in SW480, HCT116 and HT29 cells resulted in a significant 
reduction in expression level of β-catenin as shown by western blot (Figure 2.7.A). 
Adhesion assay with CacyBP overexpressed cells showed significant reduction in 
Figure 2.6.  Quantitative immunofluorescence analysis for intracellular expression of CacyBP 
and β-catenin in SW480 compared to SW620 cells. A) Fluorescent image showing up-regulation of 
CacyBP  and down-regulation of β-catenin in SW620 cells compared to SW480. Red channel 
indicates β-catenin and green channel indicates CacyBP staining. B) Quantitation for fluorescent 
intensity for CacyBP and β-catenin expression level. Data represented as mean ± SEM (n=46) based 




adhesion to fibronectin, compared to the corresponding negative controls (empty vector 




Statistical significance for reduction in adhesion characteristics was determined using 
paired t test between each over-expressed vs control cells based on 8 observations from 
two independent experiments. The corresponding p values were <0.05 for SW480 and 
HT29 cells whereas <0.001 for HCT116 cells. 
 
Figure 2.7. Role of CacyBP in cellular β-catenin level as well as CRC cell adhesion. A) Effective 
over-expression of intracellular CacyBP by CacyBP specific gene but not by control plasmid. B) 
Reduction of cellular adhesion upon successful over-expression of CacyBP in SW480, HCT116 and 
HT29 cells. C) Quantitative representation of cellular adhesion after CacyBP over-expression in 
SW480, HCT116 and HT29 cells. Data represented as mean ± SEM (n=8) based on two independent 




2.4.8. Immunocytochemistry on CacyBP over-expressed SW480 cells showed 
reduction in cellular level of β-catenin  
Immunofluorescence staining for CacyBP and β-catenin on CacyBP overexpressed 
SW480 cells showed clear reduction in β-catenin expression level with CacyBP 




Fluorescent intensity: area was measured for 54 pair of cells and significant variation 
between SW480-pXJ40 and SW480-CacyBP cell groups was analyzed using paired t test. 
P values for quatitation of β-catenin and CacyBP stained cells were <0.05 (0.0275) and 
<0.001 respectively based on 54 observations from two independent experiments. 
Figure 2.8. Quantitative immunofluorescence analysis for cellular level of CacyBP and β-catenin 
in CacyBP over-expressed SW480 cells compared to control cells. A) Fluorescent image showing 
over-expression of CacyBP caused down-regulation of β-catenin in SW480 cells but not in control 
cells. Red channel indicates β-catenin and green channels indicate CacyBP staining. B) Quantitation of 
fluorescent intensity for cellular level of CacyBP and β-catenin. Data represented as mean ± SEM 
(n=54) based on two independent experiments where ** indicates p<0.05 and *** indicates p<0.001 





A major challenge in patient management for CRC is the possibility of the tumor to be 
metastasized even after successful surgical therapy. For the diagnosis of distant 
metastasis, positron emission tomography-computed tomography (PET-CT) remains the 
best method [200] so far. However, due to their short half-lives, the wider dissemination 
of these radio-imaging approaches is hindered by the high production costs and 
transportation problems associated with the radiopharmaceuticals used for PET imaging. 
Furthermore, these techniques are not completely non-invasive [201, 202]. Therefore, 
discovery of an effective biomarker is on demand in order to overcome these problems 
while staying effective at similar sensitivity level to these imaging approaches. 
Biomarker discovery necessitates digging more information about the dynamic changes 
of primary tumor cells when they begin to metastasize. Unlike most of the reported 
studies on metastasis involving patients from different stages and focusing on one or two 
proteins [171, 172], we employed an in vitro metastatic model by comparing the whole 
cell proteome profiles of two isogenic (derived from the same patient) CRC cell lines: 
SW480 and SW620. A monoclonal origin of these two cell lines was confirmed by the 
presence of shared marker chromosomes seen on cytogenetic analysis [161]. The similar 
genetic background made it easier to study differences in phenotype, using this pair of 
cell lines. Another advantage of studying these cell lines is that there is no possibility of 
drug-induced differences, since chemotherapy was not started until after the laparotomy 
for recurrent cancer [162]. Previous studies [157, 158, 162] reported that SW620 exhibits 
enhanced  cell motility as indicated by cell migration assay and adhesion assay[162]  
together with in vivo metastasis assays [157, 158]. Our study evaluated a significant 
86 
 
alteration in the global protein landscape between these two primary and metastatic CRC 
cell lines using quantitative labeling approach like iTRAQ. Interestingly, the results we 
obtained was complementary to the earlier published reports [157, 158] enhancing the 
authenticity of our data. Down-regulation of several actin and intermediate filament 
members together with LIM domain containing proteins as mentioned by Katayama et al 
[158] showed similar fold changes as observed from our study. Although CRC shows 
highly heterogeneous behavior, it is reasonable to assume that the list of differentially 
expressed proteins in this two-cell line model will be able to represent certain 
characteristics of clinical CRC. It can thus serve as a useful reference for future research 
in CRC progression.  To further reinforce the above assumption, three other CRC cell 
lines (HCT116, HT29 and LoVo) of different metastatic potential were included in 
various stages of functional validations in our study.  
The high-throughput quantitative proteomics approach was able to identify significant 
alteration of proteins associated with cytoskeletal signaling, cellular adhesion and 
migration as well as cell death. The differential expression patterns of these proteins can 
be used to explain the pathophysiology of CRC metastasis. Gene ontology study using 
IPA with the list of significantly altered proteins revealed cellular assembly and 
organization as the topmost-ranked network which is consistent with the biological topic 
(metastasis) of our study.  
It is known that actin polymerization at the leading edge of the cell forms new anchorage 
points between the actin filaments and the matrix whereas old anchorage points are 
released at the back as the cell crawls forward [203]. Interestingly, our dataset identified 
alteration of different cytoskeletal and tight junction associated proteins that can be 
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correlated with such events, indicating possible happenings of those events in CRC 
metastasis.  Down-regulation of intermediate filaments proteins [204], desmosomal 
protein plectin-1 [205]  and plectin binding protein nesprin 3 [206] represented loss of 
inter and intra-cellular integrity. Similarly down-regulation of β-catenin [207, 208] 
together with up-regulation of CacyBP, a β-catenin degrading protein [185], down-
regulation of LIM domain containing proteins such as PDLIM4, LASP1 and LIMA1 
(refer to table 1) represented lack of focal adhesion leading to cellular detachment [209]. 
Furthermore, down-regulation of several actinin isoforms [210]
, 
[211] , actin crosslinking 
proteins like filamin A and filamin B [212] and F-actin binding protein COTL1 [213] in 
the metastatic cell, represented the same as hypothesized from review of existing 
literatures mentioned above. Alongside, up-regulation of ATP5J which has both ATPase 
(play important role in severing and depolymerization of the actin filaments [214]) and 
transporter activity [215] described the involvement of ATPase proteins in cellular 
motility by enhancing actin depolymerization. The above explanation can be used to 
describe the cellular events at the rear portion of a migrating cell which is about to detach 
itself from the surroundings [216]. However, up-regulation of some other actin binding 
proteins such as MARCKS [217] and villin [183] illustrated enhanced cellular integrity 
required for the leading edges of a crawling cell. Also up-regulation of microtubule 
dynamics regulatory protein stathmin [199]
, 
[198, 218] and down-regulation of cellular 
migration inhibitory as well as actin dynamics regulatory protein annexin A2 [188]
, 
[219] 
in SW620 cells implied enhanced cellular motility. Figure 2.9. represents the overall 












To provide new insights into CRC metastasis, one candidate protein namely CacyBP that 
was reported to degrade β-catenin [185] was chosen for further analysis in a larger panel 
of CRC cells since it has not been previously reported to be differentially expressed in 
CRC. The 26 KDa protein CacyBP was identified for the first time in mouse brain and 
Ehrlich ascites tumor (EAT) and was found to be interacting with calcyclin at a 
physiological range of Ca
2+
 indicating the possible involvement of CacyBP in Ca
2+
 
signaling pathway [220]. In 2001, Matsuzawa  et al demonstrated that Siah-1, SIP/ 
CacyBP, and Ebi collaborate in a novel pathway for β-catenin degradation linked to p53 
responses [221]. Further studies were done to evaluate the role of CacyBP in different 
cancers such as renal cell carcinoma [222] and gastric cancer [179, 223]. However no 
studies reported investigation of CacyBP on CRC progression. Furthermore, down-




regulation of β-catenin and up-regulation of a β-catenin degrading protein CacyBP [185, 
221] simultaneously in the metastatic cell, as observed in our proteomics study, provided 
a rational guide for functional validations about these two proteins. Hence the differential 
expression pattern of these two proteins were validated additionally by quantitative 
immunofluorescence studies in the same pair of cell lines as used for proteomics study, 
followed by western blot validation in three other CRC cell lines of different metastatic 
potential which implied that this protein might play an important role in CRC metastasis. 
Up-regulation of CacyBP was also validated in the mRNA level by RT-PCR as shown in 
figure 5C. Since CacyBP takes part in the proteosomal degradation of β-catenin [185] and 
was up-regulated in the metastatic cell compared to primary, over-expression of CacyBP 
in total three primary cell lines (SW480, HCT116 and HT29 as shown in figure 7) were 
performed to evaluate its impact on cellular level of β-catenin and subsequent cellular 
adhesion characteristics that represent a mode of metastasis. The results showed a 
reduction in cellular adhesion as well as decrease in β-catenin level confirming that 
cellular β-catenin level varied based on the expression of CacyBP in CRC cells. As 
mentioned earlier, CacyBP was responsible for proteosomal degradation of β-catenin 
[185] which is consistent with our finding about relative expression pattern of these two 
proteins. Furthermore, β-catenin is responsible for cellular adhesion [207, 208] which is 
found to be reduced upon CacyBP over-expression in our study. This phenomenon 
implied that CacyBP might be involved in CRC metastasis via the alteration of β-catenin 
mediated cellular adhesion. Involvements of any other detailed mechanisms are yet 
subject to further investigations which are beyond the scope of this study. However, the 
relative expression of β-catenin and CacyBP in CRC progression and its effect on cellular 
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adhesion as evaluated in our study, seems to be quite interesting trend and thus can 
probably shed new light in the field of CRC metastasis. 
In conclusion, through our study of global proteome alteration during CRC metastasis, 
we identified CacyBP as a potential biomarker which was validated functionally through 
β-catenin related cellular adhesion. Furthermore, identification of important protein 
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3.1. Summary  
Based on our previous findings that showed up-regulation of CacyBP in colorectal cancer 
(CRC) metastasis, we aimed to study detailed underlying mechanisms behind the 
involvement of this protein in CRC metastasis. CacyBP was overexpressed (CacyBP-OE) 
on primary CRC cell and knocked down (CacyBP-KD) on metastatic CRC cells that were 
subsequently examined for phenotypes related to cellular metastasis in order to verify the 
hypothesis that CacyBP-OE will increase the metastatic nature whereas CacyBP-KD will 
reduce it in corresponding cells. To further investigate the underlying molecular 
mechanism, two independent 4-plex iTRAQ based comparative proteomics experiments 
were carried out on the CacyBP-OE and CacyBP-KD cells, each with two biological 
replicates. Mining of proteomics data from both experiments showed differential 
expression of proteins related to metastatic phenotypes such as cell migration, invasion, 
adhesion and proliferation. Gene ontology analysis identified caveolar mediated 
endocytosis of integrins as the topmost network regulated by CacyBP-OE. This 
phenomenon is known to be coupled with dissociation of integrins from the focal 
adhesion complex present at the rear end of a moving cell followed by transportation of 
those dissociated integrins to the leading edge, providing traction force for cell 
movement. Hence, this result suggested a possible increase in cellular migration upon 
CacyBP-OE via integrin endocytosis which is further supported by the data obtained 
from CacyBP-KD dataset that showed down-regulation of proteins necessary for integrin 
endocytosis. Furthermore, integrin mediated cell migration is known to be influenced by 
intracellular calcium that was found to be lower in CacyBP-KD cells indicating decreased 
cell motility and higher in CacyBP-OE cells suggesting enhanced cell motility. Actin 
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nucleation by ARP-WASP complex which is known to promote cell migration, was also 
identified as one of the top regulated pathways upon CacyBP-OE. In short, this study 
presented CacyBP as a promising candidate biomarker for CRC metastasis and also shed 
light on the underlying molecular mechanism by which CacyBP promotes CRC 
metastasis. 
3.2. Introduction  
Calcyclin-binding protein or CacyBP was identified as one of the potential candidate 
biomarkers for colorectal cancer (CRC) metastasis, in our previous study [224]. This 30 
KDa protein was first discovered as a binding partner of S100A6 (calcyclin) in Ehrlich 
ascites tumor cells from mouse brain [225] and was found to interact with S100A6 in a 
calcium dependent manner [226]. Brain, liver, spleen and stomach were the major organs 
of its distribution [227]. In 2001, Matsuzawa et al showed that, CacyBP is involved in a 
novel pathway for β-catenin degradation [221], suggesting a possible involvement of 
CacyBP in tumorigenesis, thereby opening up new directions for oncogenic research. 
Initially it was thought to be involved in multiple drug resistance [228, 229] associated 
with cancer therapy and was subsequently studied for its role in cell proliferation, 
tumorigenicity and invasion [179, 223] in gastric cancer cells. CacyBP was known to 
inhibit growth in gastric cancer and renal cell carcinoma [222, 223] and was also 
associated with clinical progression in breast cancer [230]. However, these studies did not 
provide thorough knowledge on mechanistic involvement of CacyBP in corresponding 
biological processes. With respect to CRC research, this protein was only studied for its 
expression level in various stages of CRC and was known to undergo calcium dependent 
nuclear translocation [231]. Recently we discovered that increased cellular level of 
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CacyBP was associated with CRC metastasis [224]. Although we performed preliminary 
functional studies to investigate its plausible role, detailed mechanistic studies are still on 
demand which is being addressed in this present study. 
In continuation with our previous study, we have performed stable over-expression of 
CacyBP (CacyBP OE) on primary CRC cell HCT116 and stable knockdown of the same 
(CacyBP KD) on metastatic CRC cell SW620. Two non-isogenic cell lines were chosen 
to perform gene knock-in and knock-down studies for better representation of data in 
order to address the highly heterogenic behavior of clinical CRC. Cell migration, 
invasion, adhesion and proliferation assays performed on these modified cells as a 
representation of their metastatic signature verified the hypothesis that CacyBP over-
expression on primary cells will induce metastatic nature whereas its knockdown on 
metastatic cells will reduce it. Investigation about the underlying molecular mechanism 
behind this phenomenon was carried out by two independent proteomics (4-plex iTRAQ) 
experiments of the whole cell proteome from CacyBP-OE and CacyBP-KD cells. Beside 
the alterations in expression level of proteins associated with cell migration, adhesion, 
proliferation and invasion, caveolar mediated endocytosis of integrins and Actin 
nucleation by ARP-WASP complex were the two topmost canonical pathways affected 
due to CacyBP-OE as predicted from the gene ontology analyses. Actin nucleation and 
polymerization is required for cell migration [34, 37] and integrin endocytosis is known 
to be directly associated with promotion of cell migration [48, 49, 232]. An enhancement 
in both of these phenomena upon CacyBP-OE suggested a possible mechanism behind 
CacyBP mediated CRC metastasis and this fact was further supported by our knockdown 
iTRAQ results. In addition, the fact that integrin endocytosis and cell migration process is 
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affected by calcium sensing receptors [67, 233], directed us to investigate about 
intracellular calcium levels in normal and modified CRC cells from different metastatic 
potentials that showed a reduction in intracellular Ca
++
 upon CacyBP-KD and an increase 
after CayBP-OE. Validation of proteins involved in integrin endocytosis was carried out 
from both OE and KD dataset.  Our study showed that CacyBP causes CRC cells to 
become more metastatic by enhancing cell migration and also proposed possible 
mechanisms based on the proteomics results. Till date we are the first one to report this 
molecular phenomenon observed in CRC metastasis that proves CacyBP as one of the 
promising candidate proteins for further clinical studies. 
3.3. Materials and methods 
3.3.1. Generation of CacyBP over-expression construct   
Full-length cDNA encoding human CacyBP/SIP was generated from CRC SW620 cells 
by RT-PCR. The specific primers for CacyBP/SIP were 5‟ 
CCCAAGCTTGATATGGCTTCAGAAGAGCTA 3‟ (sense) and 5‟ 
CGGGATCCTCAAAATTCCGTGTCTCCTTTG 3‟ (anti-sense) [179]. The PCR product 
was cloned into pcDNA3.1(+) vector by restriction digestion at BamHI and HindIII sites 
followed by ligation reaction using T4DNA ligase (New England Biolabs) in order to 
achieve the over-expression construct, pcDNA3.1(+) -CacyBP. 
3.3.2. Generation of CacyBP- knock-down construct  
The construct for CacyBP knock-down was purchased commercially from Origene. The 
gene specific shRNA sequence used for our study was 
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GATGGAGACGATGATATGAAGCGAACCAT cloned into a shRNA expression 
vector named pGFP-V-RS. 
3.3.3. Cell transfection and generation of stable cell lines with CacyBP over-
expression and knock-down  
For generation of stable primary CRC cell line overexpressing CacyBP protein, HCT116 
(Primary CRC cell line) was seeded in a 24 well plate with 2.4×10
5
 cells per well. The 
CacyBP sense vector [pcDNA3.1(+) –CacyBP] was co-transfected with Lipofectamine 
2000 (Invitrogen) into HCT116 cells for 24 hrs and clones for stable over-expression 
were selected after 15 days of screening with G418 sulfate (800 µg/ml). Similar treatment 
was carried out with empty pcDNA3.1(+) vector separately, in order to create 
corresponding control cell line. The control and CacyBP overexpressed cells will be 
referred as HCT116-Control and HCT116-CacyBP OE respectively. 
For generation of stable metastatic CRC cell line with CacyBP knock-down, SW620 
(metastatic CRC cell line) was seeded in a 24 well plate with 2.4×10
5
 per well. The 
CacyBP ShRNA vector [pGFP-V-RS –Sh CacyBP] was co-transfected with 
Lipofectamine 2000 (Invitrogen) into SW620 cells for 24 hrs and clones for stable knock-
down were selected after 12 days of screening with puromycin (0.8 µg/ml). Similar 
treatment was done for generation of corresponding control cell line where transfection 
was carried out using pGFP-V-RS vector with noneffective sequence refered to as 
“pGFP-V-RS- Scramble” henceforth. The control and CacyBP knocked down cells will 




3.3.4. Validation of stable transfection by western blot and immunofluorescence  
 Western Blot Analysis: Western blot analysis for the validation of protein 
expression level, were carried out as described previously [224]. Primary antibody 
used included mouse anti- CacyBP/SIP antibody (diluted 1:30,000; Santa Cruz 
Biotechnology), mouse anti- actin (diluted 1:4,000; BD Transduction 
Laboratories
TM
), mouse anti-KIF4 (diluted 1:500; Santa Cruz Biotechnology), mouse 
anti-clathrin (diluted 1:500; Santa Cruz Biotechnology), mouse anti-calpain (diluted 
1:500; Santa Cruz Biotechnology), rabbit anti-VDAC-1(diluted 1:500; abcam), mouse 
anti-nucleolin (diluted 1:2000; Santa Cruz Biotechnology), mouse anti-annexin A2 
(diluted 1:1000; Santa Cruz Biotechnology), mouse anti-MARCKS (diluted 1:1000; 
Santa Cruz Biotechnology) and secondary antibodies were peroxidase-conjugated 
goat anti-mouse IgS antibody (diluted 1:5,000; BD Pharminogen
TM
) and donkey anti- 
rabbit (diluted 1:5,000; Amersham Biosciences). 
 Immunofluorescence Analysis: Immunofluorescence analysis were carried out as 
described previously [224]. HCT116-Control and HCT116-CacyBP OE as well as 
SW620-Scr Control and SW620-CacyBP KD cells were used for staining with mouse 
monoclonal anti-CacyBP antibody (Santa Cruz Biotechnology; diluted 1:2000 in 1% 
BSA with PBSCM) followed by incubation with Alexa Fluor-555 conjugated rabbit 
anti-mouse IgG (Invitrogen) at 1:200 dilutions for 1 hr each and mounted on glass 
slides with DAPI mounting solution (Santa Cruz Biotechnology). The 
immunofluorescence was analyzed under Carl Zeiss LSM 510 Meta. 
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3.3.5. Crystal violet cell proliferation assay  
HCT116-Control and HCT116-CacyBP OE cells (10×10
3
 cells per well) as well as 
SW620-Scr Control and SW620-CacyBP KD (30×10
3
 cells per well) were seeded in a 24 
well plate and allowed to get attached for overnight. After cell attachment, observation 
were made in every 24 hrs from 0 to 72 hrs. Cells were fixed with 3% paraformaldehyde 
for 30 min and dried overnight before staining with crystal violet (0.5% in 20% 
methanol) for 10 min and dried overnight again. Finally cells were treated with 1% SDS 
for 30 min and absorbance was measured at 520 nm against a blank. 
3.3.6. Adhesion assay  
Adhesion assay was performed as mentioned by [234] with certain modifications. 
Briefly, pre-coating of 96 well plate was performed with 10 μg/mL of fibronectin 
(Sigma) in PBS at 37°C for 1 hr. The wells were blocked with 0.5% BSA in culture 
medium and 0.1% BSA in medium was used as the washing buffer. HCT116-Control and 
HCT116-CacyBP OE cells as well as SW620-Scr Control and SW620-CacyBP KD cells 
were seeded as 20×10
3
 cells per well of the 96 well plate. Images for bright field of cells 
after adhesion were taken using a digital compact camera (Olympus, C-7070) attached to 
the microscope. Absorbance was measured at 550 nm after lysing with 2% SDS. 
3.3.7. Migration assay  
A 24 well companion plate (BD Biosciences) for transwell inserts were used to perform 
the cell migration assay. Briefly, the cell culture inserts were coated with 300 µl 
fibronectin at 4ºC overnight. HCT116-Control and HCT116-CacyBP OE cells (25×10
3
) 
as well as SW620-Scr Control and SW620-CacyBP KD cells (40×10
3
) were seeded on 
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the top of the insert with serum free media (400 µl) whereas the well at the bottom side of 
the insert were filled with media containing 10% FBS (500 µl). After 48 hrs incubation in 
a humidified incubator at 37ºC the cells from the top part of the insert were removed 
using a cotton bud and the cells those migrated to the bottom part of the insert were fixed 
with para-formaldehyde followed by staining with crystal violet. Images for 5 random 
fields were taken and finally the absorbance was measured at 520 nm after solubilizing 
the dye with 1% SDS. 
3.3.8. Invasion assay  
A 24 well companion plate (BD Biosciences) for Matrigel
™
 Invasion Chambers were 
used to perform the cell invasion assay. Briefly, the Matrigel
™
 Invasion Chambers were 
rehydrated with 500 µl of serum free media at 37ºC for 2 hrs. HCT116-Control and 
HCT116-CacyBP OE cells (25×10
3
) as well as SW620-Scr Control and SW620-CacyBP 
KD cells (40×10
3
) were seeded on the top of the chamber with serum free media (400 µl) 
whereas the well at the bottom side of the chamber were filled with media containing 
10% FBS (500 µl). After 48 hrs incubation in a humidified incubator at 37ºC the cells 
from the top part of the insert were removed using a cotton bud and the cells those were 
invaded through the matrigel, were fixed with paraformaldehyde followed by staining 
with crystal violet. Images for 5 random fields were taken and finally the absorbance was 
measured at 520 nm after solubilizing the dye with 1% SDS. 
3.3.9. Proteomics sample preparation  
The samples were prepared by heating the harvested cells at 100ºC for 10 min with a 
lysis buffer containing 0.5 M triethylammonium bicarbonate (TEAB), pH 8.5 and 1% 
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SDS with intermediate vortexing. The lysate was centrifuged at 12 500× g for 1 h at 15ºC 
and the supernatant was stored at -80ºC until further use. Protein quantitation was 
performed using RCDC Protein Assay Kit (Bio-Rad); 100 μg of each sample was used 
for iTRAQ labeling. 
3.3.10. iTRAQ labeling 
Two separate iTRAQ experiments were carried out with the CacyBP overexpression 
(OE) and knocked down (KD) sets using a pair of biological replicates in each case. 
iTRAQ labeling was carried out using iTRAQ Reagent 4-Plex kit (AB SCIEX) based on 
the manufacturer‟s protocol with minor modifications. A pair of HCT116-Control and 
HCT116-CacyBP OE whole cell lysates were labeled with iTRAQ labeling reagent 114 
and 116, respectively, and likewise another pair of biological replicates of the same 
samples (whole cell lysate from another batch of culture of these two cell lines) were 
labeled with 115 and 117 iTRAQ labeling reagents, respectively. Similar labeling 
approach was followed for the pair of SW620-Scr Control and SW620-CacyBP KD 


















Briefly, cell lysates were reduced with tris-(2-carboxyethyl) phosphine (TCEP), alkylated 
with methyl methane-thiosulfonate (MMTS) and diluted 20 times before digesting with 
trypsin (w/CaCl2; Promega) with a trypsin to protein ratio of 1:10 (w/w) at 37ºC for 16 h. 
The digested peptides were then dried and reconstituted with 0.5 M TEAB. The dried 
peptides were then labeled with respective isobaric tags, incubated at room temperature 
for 1 h before being combined.  
3.3.11. Strong cation exchange (SCX) chromatography 
To remove all interfering substances such as dissolution buffer, organic solvent like 
ethanol, acetonitrile, reducing agent (TCEP), alkylating agent (MMTS), SDS, calcium 
Figure 3.1. Schematic representation of the experimental design for iTRAQ labeling showing 
biological replicates from HCT116-CacyBP OE and SW620-CacyBP KD cells. In iTRAQ1, 
two biological replicates from HCT116-Control cells were labeled with 114 and 115 respectively, 
and from HCT116-CacyBP OE cells were labeled with 116 and 117 respectively. In iTRAQ2, two 
biological replicates from SW620-Scr Control cells were labeled with 114 and 115 respectively, 




chloride and excess iTRAQ reagents etc., strong cation exchange chromatography was 
carried out for the combined iTRAQ-labeled peptides using the cation exchange system 
provided in the iTRAQ Method Development Kit (AB SCIEX). The eluted fraction was 
desalted using Sep-Pak C18 cartridges (WATERS), dried and then reconstituted with 100 
μL of 5% ACN and 0.05% FA for 2D LC_MS/MS analysis. 
3.3.12. 2D LC analysis and tandem mass spectrometry (MS/MS)  
The first dimension peptide separation was performed using the Ultimate LC system 
(Dionex-LC-Packings, Sunnyvale, CA) connected to a strong cation-exchange (SCX) 
column. 96 μg (via multiple injections) of the labeled peptide mixture was injected using 
the micro-pickup loop mode into a Zorbax Bio-SCX II column (3.5 µm, 50 × 0.8 mm; 
Agilent, SantaClara, CA). SCX mobile phase A was 5% ACN and 0.05% FA and mobile 
phase B was 5% ACN, 500 mM NaCl and 0.05% FA. The flow rate was set at 10 µl/min. 
A total of 78 fractions were eluted (2 min each) and collected on a 96 well v-bottom plate 
using step gradients of mobile B as follows: 0% for 10 min, 0-20% for next 90 min, 20-
60% for next 20 min and 60-100% for last 10 min and continued at the same %B for 
another 25 min. The eluted fractions were subsequently combined to 10 and 12 fractions 
respectively for overexpression and knockdown iTRAQ batch and then desalted with 
Sep-Pak® tC18 µElution Plate (186002318, WATERS Corp., Milford, MA) using a 
vacuum manifold (Millipore) in accordance to the manufacturer‟s recommendations 
before second-dimension reverse phase (RP) chromatography. From each fraction, 2 µg 
was trapped on a precolumn (200 µm x 0.5 mm) and then eluted on an analytical column 
(75 µm x 150 mm) for separation. Both columns were packed with Reprosil-Pur C18-AQ 
3 µm 120Å phase (Eksigent, Dublin, CA). The RP mobile phase A was 98% H2O (with 
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0.1% FA) while RP mobile phase B was 98% ACN (with 0.1% FA). The peptides were 
separated by a linear gradient of 12-30% of mobile B in 90 min at a flow rate of 300 
nl/min. The MS analysis was performed using a 5600 TripleTOF analyzer (QqTOF; AB 
SCIEX) in Information Dependent Mode. Precursor ions were selected across the mass 
range of 400-1800 m/z using 250 ms accumulation time per spectrum. A maximum of 20 
precursors per cycle from each MS spectra were selected for MS/MS analyses with 100 
ms minimum accumulation time for each precursor and dynamic exclusion for 15s. 
Tandem mass spectrometry was recorded in high sensitivity mode with rolling collision 
energy on and iTRAQ reagent collision energy adjustment on.     
3.3.13. Peptide and protein identification  
Protein identification and relative iTRAQ quantification were performed with 
ProteinPilot™ Software 4.2 (AB SCIEX) using the Paragon™ algorithm for the peptide 
identification which was further processed by Pro Group
TM
 algorithm where isoform-
specific quantification was adopted to trace the differences between expressions of 
various isoforms. User defined search parameters were as follows: (i) Sample Type: 
iTRAQ 4plex (Peptide Labeled); (ii) Cysteine Alkylation: MMTS; (iii) Digestion: 
Trypsin; (iv) Instrument: TripleTOF 5600; (v) Special Factors: None; (vi) Species: Homo 
sapiens; (vii) ID Focus: Biological modifications; (viii) Database: 
ipi.HUMAN.v3.87.fasta; (ix) Search Effort: Thorough; (x) FDR Analysis: Yes; (xi) User 
Modified Parameter Files: No. For iTRAQ quantitation, the peptide for quantification 
was automatically selected by Pro Group
TM
 algorithm to calculate the reporter peak area, 
error factor (EF) and p value. The resulting dataset was auto bias-corrected to get rid of 
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any variations imparted due to the unequal mixing during the combination of different 
labeled samples.  
A reverse database search strategy was adopted to estimate the false discovery rate (FDR) 
for peptide identification. For both of our iTRAQ studies, a strict unused confidence 
cutoff >1.3 was used as the qualification criteria, which corresponds to a peptide 
confidence level of 95%. With this filter, the corresponding false discovery rate (FDR= 
0.0575% for the OE set and 0% for the KD set) was calculated from the decoy hits. The 
results were then exported into Microsoft Excel for manual data interpretation. 
Subsequently, the meaningful cut-off for up-regulation (≥ 1.25) and down-regulation (≤ 
0.80) of proteins was finalized by the use of biological replicate method proposed by Gan 
et al [178, 224]. 
3.3.14. Bioinformatics analysis (Gene ontology study)  
To better appreciate the data set generated, protein list of significantly altered proteins 
was uploaded into Ingenuity Pathway Analysis (IPA) software server 
(http://www.ingenuity.com) and analyzed using the Core Analysis module to rank the 
proteins into top biological functions as well as canonical pathways involved. The 
reference set and parameters for Ingenuity Pathway Analysis (IPA) on significantly 
altered protein list was as follows: (i) Reference set, Ingenuity Knowledge Base (Genes 
Only); (ii) Relationship to include, Direct and Indirect; (iii) Filter Summary, Consider 
only molecules and/or relationships where (species = Human OR Rat OR Mouse) AND 
(confidence = High (predicted) OR Experimentally Observed). 
106 
 
3.3.15. Intracellular calcium level measurement 
Cells were plated in low density and incubated overnight until attachment and 60% 
confluence. They were washed with PBSCM and incubated with 30 µM fluo-3AM 
(diluted in PBSCM) dye for 1 hour. After washing out the dye with PBSCM, 30 minute 
interval was allowed for intracellular de-esterification of the dye before taking 
photographs under Carl Zeiss LSM 510 Meta. 
3.3.16. Statistical analysis  
Statistical analyses were conducted with GraphPad Prism 5 software. One way analysis 
of variance method was used to compare between HCT116, SW480 and SW620 cells, 
whereas comparison between HCT116-Control and HCT116-CacyBP OE as well as 
SW620-Scr Control and SW620-CacyBP KD were estimated using two-tailed unpaired t 
test. p value less than 0.05 was considered as statistically significant for each cases. 
3.4. Results 
Our previous study [224] showed higher expression levels of CacyBP in CRC metastatic 
cells compared to the primary cells and hence suggested possible involvement of this 
protein in the process of CRC metastasis. In present study, we carried out gene knock-in 
and knock-down experiments for CacyBP in CRC cells of different metastatic potential in 
order to investigate about the molecular mechanism through which CacyBP affects the 
process of CRC metastasis. Following the trend in expression level of CacyBP in our last 
proteomic experiment, we performed over-expression (OE) on primary CRC cell 
HCT116 and knock-down (KD) on metastatic CRC cell SW620. 
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3.4.1. Confirmation of stable over-expression and knockdown of CacyBP in CRC                         
cell lines   
As mentioned in the experimental procedures, CacyBP was overexpressed in a primary 
CRC cell line, HCT116 and was knocked down in a metastatic CRC cell line, SW620. 
The expression level of CacyBP in HCT116-Control versus HCT116-CacyBP OE cells as 
well as SW620-Scr Control versus SW620-CacyBP KD cells were confirmed by western 
blot as well as immunofluorescence (CacyBP staining was shown in red) studies (Figure 
3.2). Twenty-five pairs of cells were considered for the quantitative analysis 
(fluorescencent intensity: area) done by the immunofluorescence study. The p value for 
quantitation against CacyBP staining was < 0.0001 for both OE and KD cells compared 
to their corresponding control cells when calculated by unpaired two tailed t test based on 















3.4.2. CacyBP over-expression and knock-down have an influence on cell 
proliferation  
Cell proliferation was monitored in the transfected cells using crystal violet staining assay 
that showed a reduced proliferation rate of primary HCT116 cells after CacyBP 
overexpression compared to the corresponding control. At the same time, an increased 
proliferation rate was observed upon CacyBP knock-down on metastatic SW620 cells as 
compared to the corresponding control cell line (Figure 3.3).  
Figure 3.2. Validation of CacyBP over-expression and knock-down. A) Western blot validation of 
CacyBP expression level in HCT116-Control, HCT116-CacyBP OE, SW620-Scr Control and SW620-
CacyBP KD cells.  Actin was used as a loading control. B) Immunofluorescence analysis confirming 
over-expression of CacyBP in HCT116-CacyBP OE cells compared to HCT116-Control and knock-
down of CacyBP in SW620-CacyBP KD cells compared to SW620-Scr Control cells.  Red channel 
indicates CacyBP staining. B) Quantitation for fluorescent intensity for CacyBP expression level. Data 
represented as mean ± SEM (n=25) based on two independent experiments where *** indicates 






3.4.3. CacyBP exression has an impact on cellular adhesion characteristics  
Cellular adhesion assay on transfected cells using fibronectin as a coat, showed 
significant reduction in adhesion characteristics in HCT116-CacyBP OE cells as 
compared to HCT116-Control (Figure 3.4A) whereas an increase in adhesion 
characteristics was observed in SW620-CacyBP KD  cells when compared to SW620-Scr 
Control cells (Figure 3.4B). Statistical significance for variation in cellular adhesion 
characteristics was determined using unpaired two-tailed t test between each OE/KD cells 
vs. control cells based on 9 observations from three independent experiments. The 




Figure 3.3. Effect of CacyBP expression level on cell proliferation. A) Decrease in cellular 
proliferation rate was observed in HCT116-CacyBP OE cells as compared to HCT116-Control cells.  B) 
Increase in cellular proliferation rate was observed in SW620-CacyBP KD cells as compared to SW620-







3.4.4. CacyBP affects cell migration  
HCT116-CacyBP OE cells migrated significantly faster than HCT116-Control cells 
(Figure 3.5.A) when measured on a chemotaxis assay platform whereas migration was 
reduced in SW620-CacyBP KD  cells compared to  SW620-Scr Control cells (Figure 
3.5.B). Statistical significance for migration characteristics was determined using 
unpaired two-tailed t test between each OE/KD cells vs. control cells based on 10 
Figure 3.4. Effect of CacyBP expression level on cellular adhesion. A) Cellular adhesion was 
decreased in HCT116-CacyBP OE cells compared to HCT116-Control cells.  B) Increase in cellular 
adhesion characteristics was observed in SW620-CacyBP KD cells as compared to SW620-Scr 
Control cells. Quantitation values for cellular adhesion was presented as mean ± SEM (n=9) based on 
three independent experiments where *** indicates p<0.0001 and ** indicates p<0.001 using two 




observations from three independent experiments. The corresponding p values were 
0.0029 for OE set and 0.011 for KD set respectively. 
 
 
3.4.5. CacyBP influences cell invasion  
Invasion assay performed on 24 well matrigel invasion assay chamber showed a 
significant increase in invasive nature for HCT116-CacyBP OE cells when compared to 
HCT116-Control cells (Figure 3.6.A), whereas SW620-CacyBP KD  cells showed 
reduced invasion compared to  SW620-Scr Control cells (Figure 3.6.B). Statistical 
significance for invasion characteristics was determined using unpaired two-tailed t test 
between each OE/KD cells vs. control cells based on 8 observations from two 
Figure 3.5. CacyBP affects cell migration. A) Cell migration was increased in HCT116-CacyBP 
OE cells compared to HCT116-Control cells.  B) Decreased cell migration was observed in SW620-
CacyBP KD cells as compared to SW620-Scr Control cells. Quantitation values for cell migration 
was presented as mean ± SEM (n=10) based on three independent experiments where * indicates 




independent experiments. The corresponding p values were <0.0001 for OE set and 












3.4.6. iTRAQ profiling of HCT116- control versus CacyBP-OE (OE set) and SW620-
Scr control versus CacyBP-KD (KD set) 
To understand the global proteomic alteration due to CacyBP expression level change in 
CRC cell lines of different metastatic potential, protein extracts from HCT116-CacyBP 
OE and HCT116-Control cells (OE set) as well as SW620-CacyBP KD and SW620-Scr 
Control cells (KD set) were analyzed in two independent iTRAQ experiments (Figure 
3.1.). Results of these two proteomics experiments were correlated to explain molecular 
phenomenon involved in CRC metastatic process. Two biological replicates for each cell 
Figure 3.6. CacyBP has an impact on cell invasion. A) HCT116-CacyBP OE cells showed 
enhanced invasion as compared to HCT116-Control cells.  B) Decreased cellular invasive nature 
was observed in SW620-CacyBP KD cells in comparison to SW620-Scr Control cells. 
Quantitation values for cell invasion was presented as mean ± SEM (n=8) based on two 
independent experiments where * indicates p<0.05 and *** indicates p<0.0001 using two tailed 




lines were compared for analysis of dataset as well as to measure the variation caused by 
random biological effects. A strict cutoff for unused protein score ≥1.3 was used as the 
first qualification criterion which corresponds to a 0.0575% global false discovery rate 
(global FDR) for OE set and 0% global FDR for KD set. With this filter, the iTRAQ 
experiment identified total 2335 proteins for the OE set and 2733 proteins for the KD set 
(Supplementary table 3.1. and 3.2., appendix soft copy). Out of these, more than 65% 
proteins correspond to >3 peptide match for OE set whereas for KD set more than 75% 
proteins correspond to >3 peptide match. Subsequently the final cutoff ratio for up- or 
down-regulation of proteins was determined by comparing the control versus control 
ratios (ideally it is supposed to be 1 and any variation beyond that is due to random 
biological variations) and calculating their variations from 1. Since biological variation 
has the highest variation with lower number of proteins covered when compared to 
technical or experimental replicates, fixing a cutoff with the biological variation enhances 
the certainty that the observed protein alteration is real and thereby eliminates the need 
for other types of replicates [178]. Applying this method to both of our datasets, we 
observed about 25% variation for both OE and KD dataset corresponding to 95% 
coverage of data (Figure 3.7.). Based on this, the cutoff was fixed at 1.25 fold (25% 
variation) corresponding to the iTRAQ ratio of >1.25 for up-regulation and <0.80 for 
down-regulation. These cutoff thresholds were then applied in the two biological 
replicates (Replicate 1, 116:114 and replicate 2, 117:115) for the OE set. Whereas for KD 
set, cross comparison between biological replicates were also considered since cells were 
passaged and harvested together on the same day unlike the OE set. Therefore the 4 
replicates for KD set were as follows: replicate 1- 116:114, replicate 2- 117:115, replicate 
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3- 116:115 and replicate 4- 117:114.  Only common proteins which passed the criteria in 
all the replicates were considered as significantly altered in expression level. A total of 
284 and 450 proteins were identified as significantly altered in the OE and KD datasets 
respectively. Out of these, 146 (51.4%) were up-regulated and 138 (48.6%) were down-
regulated for the OE dataset whereas 213 (47.33%) were up-regulated and 237 (52.67%) 
were down-regulated for the KD dataset. Less than 10% of these proteins correspond to a 




3.4.7. Gene ontology study for the significantly altered proteins  
Gene Ontology studies using Ingenuity Pathway Analysis software classified the 
significantly altered proteins as per their biological functions (Table 3.1 & 3.2) as well as 
ranked them as per their involvement in certain canonical pathways (Figure 3.8; 
Supplementary figure 3.1., appendix). Interestingly, caveolar mediated endocytosis was 
Figure 3.7. Determination of experimental variation using all the identified proteins (Unused score > 
1.3) common in both biological replicates: The horizontal axis represents % variation of iTRAQ ratios 
(ratios of same protein from different biological replicates) from 1. The primary vertical axis represents 
the corresponding number of proteins (bars) having different % variation. The secondary vertical axis 
represents the cumulative % of the counted proteins (lines). More than 95% of the proteins had less than 
25% of variation due to random biological effects justifying the true regulation cut-off at 1.25 fold. A)  




the topmost pathway affected upon CacyBP-OE with all the integrin subunits associated 
in this pathway and all of them were up-regulated. This phenomenon can be looked upon 
as an enhanced endocytosis of integrins leading to increased cell migration [48, 232]. 
Actin nucleation by ARP-WASP complex, which is known to promote cell migration was 










3.4.8. Relevance of iTRAQ dataset proteins with CRC metastasis 
In order to investigate CacyBP‟s role in the molecular events of CRC metastasis, we 
performed iTRAQ based proteomics analysis on whole cell lysate from CacyBP OE and 
KD cells. Significantly altered proteins from both datasets (OE dataset and KD dataset) 
were classified based on their biological function as well as involvement in important 
canonical pathways.  
Figure 3.8. Ingenuity Pathway Analysis for significantly altered proteins from CacyBP-OE 
dataset. Top 5 cannonical pathways to which the significantly altered proteins are associated 
with (Diagram redrawn based on original output file shown in supplementary figure 3.1., 
appendix). Caveolar mediated endocytotic signaling was the topmost hit and actin nucleation via 




3.4.8.1. Proteins from the CacyBP-OE-iTRAQ dataset explain CacyBP’s 
involvement in CRC metastasis 
 Proteins involved in cell proliferation: Over-expression of CacyBP on primary CRC 
cell line HCT116 caused up-regulation of proteins that inhibit cellular proliferation 
process and down-regulation of proteins that favor cell proliferation (Table 3.1.). 
Annexin A1, Protein disulfide-isomerase A3 and 14-3-3 protein gamma [235-237] 
were up-regulated whereas EPCAM or Epithelial cell adhesion molecule and FTL or 
Ferritin light chain protein [238, 239] were down-regulated interpreting an overall 
decrease in cellular proliferation rate which is in conformity with the crystal violet 
assay results. 
 Proteins involved in cell migration: An overall increase in cell migration ability was 
observed after CacyBP over-expression on HCT116 cells as compared to the 
corresponding control cells. This phenomenon can be explained by the differential 
expression pattern of certain proteins involved in cell migration (Table 3.1.). Up-
regulation of migration facilitators such as Calcium and integrin-binding protein 1, 
Isoform 1 of Integrin alpha-3, Isoform 9 of Integrin alpha-6, Isoform 2 of Integrin 
alpha-V, Isoform Beta-4D of Integrin beta-4, Myosin regulatory light chain, S100A4 
Protein, Gamma-synuclein, STAT1 protein and MARCKS [217, 232, 240-245] as 
well as down-regulation of migration inhibitors such as Annexin A2 (Isoform 1) and 
Galectin-1 [188, 246, 247] was observed in the OE iTRAQ dataset. 
 Proteins involved in cell invasion: Primary CRC cell HCT116 became more 
metastatic and hence more invasive in nature when CacyBP was overexpressed, as 
shown in the invasion assay. This finding is in conformity with the iTRAQ dataset as 
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we found up-regulation of proteins that have a positive impact on cellular invasion 
whereas down-regulation of proteins that inhibit invasion process (Table 3.1.). For 
example, Annexin A1, COL18A1 protein, Isoform 2 of Integrin alpha-V, Isoform 
Beta-4D of Integrin beta-4, MARCKS or Myristoylated alanine-rich C-kinase 
substrate and transgelin [248-253] were found to be up-regulated. On the other hand, 
down-regulation of CBX5 22 kDa protein, DIAPH1 protein and Isoform 3 of HCLS1-
associated protein X-1 [254-256] were observed representing an overall increase in 
invasive nature of the cells. 
 Proteins involved in cell adhesion: Reduction in cellular adhesion characteristics 
upon CacyBP over-expression can be correlated with the down-regulation of certain 
cellular adhesion molecules (Table 3.1.) such as Isoform 3 of Rho guanine nucleotide 
exchange factor 1, EPCAM or Epithelial cell adhesion molecule and ALCAM protein 
[257-259]. 
 Topmost canonical pathways regulated upon CacyBP overexpression- Caveolar 
mediated endocytosis and actin nucleation: Caveolar mediated endocytosis was 
identified as the topmost regulated network through gene ontology studies via 
Ingenuity Pathway Analysis (IPA) and the proteins involved in this network were 
Integrin alpha-2, Isoform 1 of Integrin alpha-3, Isoform 9 of Integrin alpha-6, Isoform 
2 of Integrin alpha-V and Isoform Beta-4D of Integrin beta-4. All of these were up-
regulated in our OE-iTRAQ dataset. This result showed a high possibility of 
increased integrin internalization via caveolar mediated endocytosis that resulted in 
ultimate increase in cell migration [48, 49, 232] caused upon CacyBP over-expression 
(Table 3.1.). More proteins associated with this event were found to be differentially 
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expressed in both of our iTRAQ datasets and are discussed in detail in the discussion 
section. 
Actin nucleation by ARP-WASP complex was found to be the next hit as the top 
network in Ingenuity Pathway Analysis and the molecules involved in this network 
were Integrin alpha-2 and Isoform 1 of Integrin alpha-3 both of which was up-
regulated in the OE dataset (Table 3.1.). 
 






















Proteins associated with cellular proliferation 
47.75 78.6 IPI00218918.5 Annexin A1 58 1.37± 0.04 ↑ 




82 1.39± 0.04 ↑ 











27 0.79± 0.01 ↓ 
6 30.3 IPI01014563.1 
Ferritin light 
chain 
3 0.71± 0.08 ↓ 
Proteins involved in cell Migration 




2 1.45± 0.17 ↑ 
23.1 17.1 IPI00215995.1 
Isoform 1 of 
Integrin alpha-3 
18 1.47± 0.13 ↑ 
14.86 23.9 IPI00921401.1 
Isoform 9 of 
Integrin alpha-6 
11 2.56± 0.08 ↑ 
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10.99 24 IPI00555991.2 
Isoform 2 of 
Integrin alpha-
V 
9 1.88± 0.24 ↑ 
48.23 35.1 IPI00220847.2 
Isoform Beta-
4D of Integrin 
beta-4 
34 1.47± 0.04 ↑ 




5 1.53± 0.23 ↑ 




12 73.2 IPI00297714.2 
Gamma-
synuclein 
9 2.31± 0.06 ↑ 
12.51 22.1 IPI00795482.1 
STAT1 83 kDa 
protein 
8 2.44± 0.54 ↑ 








68.14 72.9 IPI00455315.4 
Isoform 1 of 
Annexin A2 
78 0.77± 0.01 ↓ 
22.22 76.3 IPI00219219.3 Galectin-1 33 0.62± 0.02 ↓ 
Proteins involved in cellular invasion 
47.75 78.6 IPI00218918.5 
ANXA1 
Annexin A1 
58 1.37± 0.04 ↑ 




2 1.83± 0.03 ↑ 
10.99 24 IPI00555991.2 
Isoform 2 of 
Integrin alpha-
V 
9 1.88± 0.24 ↑ 
48.23 35.1 IPI00220847.2 
Isoform Beta-
4D of Integrin 
beta-4 
34 1.47± 0.04 ↑ 








16.4 49.1 IPI00647915.1 
TAGLN2 24 
kDa protein 
13 1.73± 0.20 ↑ 




16 0.69± 0.03 ↓ 
2 14.6 IPI00954512.1 




1 0.76± 0.02 ↓ 
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6.11 55.3 IPI01021488.1 
CBX5, 22 kDa 
protein 
5 0.56± 0.21 ↓ 
Proteins engaged in cellular adhesion 
12.14 25.6 IPI00395605.4 





7 0.65± 0.07 ↓ 




27 0.79± 0.01 ↓ 





8 0.72± 0.06 ↓ 
Proteins involved in caveolar mediated endocytosis 
13.54 16.8 IPI00013744.1 Integrin alpha-2 9 1.33± 0.06 ↑ 
23.1 17.1 IPI00215995.1 
Isoform 1 of 
Integrin alpha-3 
18 1.47± 0.13 ↑ 
14.86 23.9 IPI00921401.1 
Isoform 9 of 
Integrin alpha-6 
11 2.56± 0.08 ↑ 
10.99 24 IPI00555991.2 
Isoform 2 of 
Integrin alpha-
V 
9 1.88± 0.24 ↑ 
48.23 35.1 IPI00220847.2 
Isoform Beta-
4D of Integrin 
beta-4 
34 1.47± 0.04 ↑ 




2 1.45± 0.17 ↑ 
70.9 33.9 IPI00298994.6 Talin-1 49 1.39± 0.07 ↑ 
Proteins involved in ARP-WASP mediated actin nucleation 
13.54 16.8 IPI00013744.1 Integrin alpha-2 9 1.33± 0.06 ↑ 
23.1 17.1 IPI00215995.1 
Isoform 1 of 
Integrin alpha-3 
18 1.47± 0.13 ↑ 
 
a
 These proteins have met the criteria (i.e. unused protein score > 1.3 and change in 
expression level of at least 1.25 fold for HCT116-CacyBP OE vs. HCT116-Control cell) 




3.4.8.2. Proteins from the CacyBP-KD-iTRAQ dataset explain CacyBP’s 
involvement in CRC metastasis 
 Proteins involved in cell proliferation: The iTRAQ dataset for CacyBP-KD showed 
over-expression of certain proteins (Table 3.2.) that were known to promote cell 
proliferation. These were Alpha-actinin-4, Isoform 2 of BH3-interacting domain 
death agonist protein, C1QBP or Complement component 1 Q subcomponent-binding 
protein, Fos-related antigen 1, Isoform 1 of Stathmin and S100A11 [260-265], which 
concluded an overall increase in cell proliferation rate. Crystal violet assay for 
measurement of cell growth also showed significant increase in cell proliferation rate 
upon CacyBP knock-down on metastatic SW620 cells.  
 Proteins involved in cellular assembly and organization: Proteins involved in focal 
adhesion as well as maturation of intercellular junction were found to be differentially 
expressed upon CacyBP Knock down in SW620 cells showing an overall effect of 
enhanced cellular adhesion (Table 3.2.). Histone deacetylase 1, PAK4 or Isoform 1 of 
Serine/threonine-protein kinase PAK 4 and Isoform 2 of Solute carrier family 12 
member 2 were down regulated in our dataset explaining a more stable morphology 
since over-expression of these protein is related to epithelial messenchymal transition 
[266-268]. On the other hand, C1QBP or Complement component 1 Q 
subcomponent-binding protein, and Integrin alpha-6 were up-regulated and are 
known to enhance cellular adhesion [269, 270]. Proteins improving focal adhesion 
such as CIB1 or Calcium and integrin-binding protein 1 [240, 271] was up-regulated 
whereas EHD1 or EH domain-containing protein 1, and RTKN or Isoform 1 of 
Rhotekin [272, 273] were down-regulated providing a resultant outcome of improved 
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cellular adhesion. Adhesion assay performed on SW620-CacyBP KD and SW620-Scr 
Control cells showed similar effect. 
Proteins involved in cytoskeleton organization were also differentially expressed 
reflecting a more stable cellular backbone after CacyBP knock-down compared to the 
corresponding scrambled control cell line (Table 3.2.). Actin capping protein GAP43 
neuromodulin isoform 1 [274], microtubule dynamics controlling protein MAP1B or 
Microtubule-associated protein 1B and MAP4 or Isoform 1 of Microtubule-associated 
protein 4 [275, 276], neuronal actin binding protein DBN1 [277], cytoskeleton 
organization protein Dysbindin [278] and kinectin, an integral member of focal 
adhesion as well as actin filament organization [279] were found to be up-regulated in 
the KD iTRAQ dataset which interprets difference in cytoskeleton organization from 
wild type metastatic cells. Moreover, LASP1 or Isoform 1 of LIM and SH3 domain 
protein 1 and PDLIM7 or Isoform 1 of PDZ and LIM domain protein 7 [280] were 
up-regulated in our dataset whereas these proteins were down-regulated in our 
previous iTRAQ study [224] when primary (SW480) versus metastatic (SW620) 
CRC whole cell proteome were compared. 
 Proteins involved in integrin internalization and calcium signaling: Thorough 
screening of the KD iTRAQ dataset picked up proteins related to integrin endocytosis 
(Table 3.2.). The expression trend of these proteins upon CacyBP knock-down 
interpreted an effect opposite to those observed in the OE iTRAQ dataset. Calpain-1 
[281], Clathrin heavy chain 1, kinesin KIF4A [48, 49] and EH domain-containing 
protein 1 [273] were down regulated showing an overall reduction in integrin 
internalization and hence reduced migration of cells. Moreover, Calpain-1 is a 
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protease that is activated by intracellular calcium influx and dissociate integrins from 
focal adhesion complex [281]. As per the data from our intracellular calcium level 
measurement, CacyBP-KD cells had a lower intracellular calcium level that might 
lead to calpain inactivation. On the other hand calcium homeostasis maintaining 
protein VDAC-1 was down- regulated suggesting one of the reasons behind the lower 
intracellular calcium [282]. 
 
 






















Proteins involved in Cell proliferation 
102.3 64.3 IPI00013808.1 Alpha-actinin-4 154 1.55± 0.06 ↑ 
5.83 34.9 IPI00420084.3 




4 1.38± 0.06 ↑ 
23.92 38.7 IPI00014230.1 
Complement 




38 1.40± 0.03 ↑ 
4 30.6 IPI00011590.1 
Fos-related 
antigen 1 
2 2.07± 0.25 ↑ 
2 9.5 IPI00013895.1 S100A11 Protein  1 1.72± 0.16 ↑ 
26.17 53.7 IPI00479997.4 
Isoform 1 of 
Stathmin 
23 1.46± 0.05 ↑ 
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Proteins involved in focal adhesion 
23.92 38.7 IPI00014230.1 
Complement 




38 1.40± 0.04 ↑ 




34 1.36± 0.04 ↑ 




1 1.70± 0.11 ↑ 




7 0.72± 0.02 ↓ 
6 17.8 IPI00029834.3 
Isoform 1 of 
Rhotekin 
3 0.31± 0.04 ↓ 
7.06 25.1 IPI00013774.1 
Histone 
deacetylase 1 
5 0.69± 0.04 ↓ 
4.01 13.4 IPI00014068.1 




3 0.62± 0.07 ↓ 
22.47 23.4 IPI00220844.1 




12 0.75± 0.02 ↓ 
Proteins involved in cytoskeleton organization 
6 60.6 IPI00791316.1 
Neuromodulin 
isoform 1 
3 2.63± 0.25 ↑ 




84 1.47± 0.05 ↑ 
97.37 68.8 IPI00396171.4 




74 1.63± 0.05 ↑ 
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18 1.39± 0.01 ↑ 
4 11.6 IPI00394984.3 
Isoform 2 of 
Dysbindin 
2 1.48± 0.12 ↑ 
87.8 53.9 IPI00328753.1 
Isoform 1 of 
Kinectin 
60 1.37± 0.02 ↑ 
27.5 58.2 IPI00000861.1 
Isoform 1 of 
LIM and SH3 
domain protein 1 
36 1.60± 0.04 ↑ 
11.41 44.6 IPI00023122.1 
Isoform 1 of 
PDZ and LIM 
domain protein 7 
12 1.53± 0.03 ↑ 
Proteins involved in integrin internalization 
87.8 53.9 IPI00328753.1 
Isoform 1 of 
Kinectin 
60 1.37± 0.02 ↑ 
11.39 23.5 IPI00011285.1 
Calpain-1 
catalytic subunit 
7 0.61± 0.07 ↓ 
38.78 28.3 IPI00455383.4 
Isoform 2 of 
Clathrin heavy 
chain 1 
32 0.70± 0.03 ↓ 
8.89 25.9 IPI00556059.1 




6 0.37± 0.05 ↓ 




7 0.72± 0.02 ↓ 
 
a
These proteins have met the criteria (i.e. unused protein score > 1.3 and change in 
expression level of at least 1.25 fold for SW620-CacyBP KD vs. SW620-Scr Control 
cell) as defined in the “materials and method” as well as “results” section. 
 
3.4.9. Validation of iTRAQ dataset proteins  
3 proteins identified in the OE dataset and 5 proteins identified in the KD dataset were 
validated for their differential expression pattern using western blot. Annexin A2 and 
nucleolin were found to be down-regulated whereas MARCKS was up-regulated in 
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CacyBP- OE cells compared to the control one (Figure 3.9.A). This finding is in 
conformity with the iTRAQ results. Similarly, in CacyBP- KD cells, clathrin, kinesin, 
calpain and VDAC-1 were found to be down-regulated whereas nucleolin was up-
regulated compared to the corresponding control cell line, maintaining consistency with 
the iTRAQ data (Figure 3.9.B). 
 
 
3.4.10. Intracellular calcium level measurement  
Measurement of intracellular calcium abundance through confocal microscopic method 
(Fluo 3AM staining showed in green channel) showed higher abundance in metastatic 
SW620 cells when compared to primary HCT116 and SW480 (Figure 3.10.A). 
Comparison of intracellular calcium level between two primary cell lines (HCT116 and 
SW480) did not show any significant differences. Comparison was done between 
HCT116-CacyBP OE and HCT116-Control cells as well as SW620-CacyBP KD and 
SW620-Scr Control cells. Overexpressed cells showed an increase in intracellular 
calcium level whereas knockdown of CacyBP resulted in a reduction in intracellular 
calcium level (Figure 3.10.B). Two-tailed unpaired t test was used to calculate statistical 
Figure 3.9. Validation of iTRAQ (both CacyBP-OE and CacyBP-KD dataset) results A) Western-blot 
studies to validate differential expression pattern of 3 candidate proteins from OE dataset: Annexin A2 and 
nucleolin were down-regulated whereas MARCKS was up-regulated in CacyBP- OE cells compared to the 
control cells which were in conformity with the iTRAQ results. B) Western blot validation of 5 candidate 
proteins from KD dataset: clathrin, kinesin, calpain and VDAC-1 were found to be down-regulated whereas 




significance for the quantitation (fluorescencent intensity: area) between OE/KD cells vs. 
control cells and one-way analysis of variance method was used to compare between 
HCT116, SW480 and SW620 cells. The p value for quantitation against intracellular 
calcium staining was 0.003 for OE set and <0.0001 for KD set whereas the p value for 
quantitation for HCT116 vs. SW620 and SW480 vs. SW620 were <0.05. All calculations 




Figure 3.10.  Intracellular Ca
++
 level in normal and genetically modified primary and metastatic 
CRC cells. A) Fluorescent image showing enhanced intracellular Ca
++
 level in metastatic SW620 cells 
compared to primary HCT116 and SW480 cells. Statistical significance was calculated using one way 
analysis of variance method. B) Fluorescent image showing enhanced intracellular Ca
++
 level in HCT116-
CacyBP OE cells compared to HCT116-Control cells and reduced intracellular Ca
++
 level in SW620-
CacyBP KD cells as compared to SW620-Scr Control cells. Green channel indicates Fluo 3AM staining 
for intracellular calcium. Statistical significance was calculated using two tailed unpaired t test. 
Quantitation values for fluorescent intensity/ area (mm
2
) were represented as mean ± SEM (n=20) based 
on two independent experiments where ns indicates not significant, * indicates p<0.05, ** indicates 





CacyBP is a comparatively new protein candidate in oncology research. Though several 
studies have indicated its role in cell proliferation, tumorigenicity and invasion for 
specific cancer subtypes [179], yet the underlying mechanisms involved in metastasis are 
not well understood. Some authors opine that CacyBP/ SIP binds to Siah-1 and Skp 1 
(components of ubiquitin ligase) to degrade β-Catenin [221], which is known for its 
capability to regulate many oncogenic signaling networks [283-285]. Even then, the 
precise pathological role of CacyBP particularly in cancer metastasis remains unknown. 
We were the pioneer to propose its contribution in CRC metastasis as observed through 
proteomics based experimentation [224] that subsequently lead us to investigate the 
detailed mechanisms as described here.  
Considering that CacyBP might play a pivotal role in CRC metastasis, we performed 
over-expression and knock-down of the protein in (CRC) cells of different metastatic 
potential to confirm its complementary outcome. Two non-isogenic cell lines (Primary 
HCT116 and metastatic SW620) were used to perform these gene knock-in and knock-
down experiments respectively, to normalize the heterogeneity exhibited by clinical 
CRC. Since cellular CacyBP level is enhanced in metastasis as confirmed from our 
previous study on metastatic and primary cells, we hypothesized that forced CacyBP 
expression in primary cells might develop metastatic phenotypes while reduced CacyBP 
levels might decrease the metastatic potential of a highly metastatic cell. Our experiments 
for cell migration, invasion, adhesion and proliferation assays on the modified cells 
confirmed this hypothesis. Especially, over-expression of CacyBP on primary CRC cell, 
significantly increased its metastatic nature (Figure 3.3-3.6). To further investigate the 
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underlying molecular mechanisms we performed proteomics-based experiments on the 
overexpressed (OE) and knocked down (KD) cells. Two independent 4-plex iTRAQ 
experiments were carried out from the whole cell lysate of OE and KD cells and the 
comparison was done against the corresponding control cells.  
Proteomics data from both the datasets revealed differentially expressed proteins that are 
associated with different cellular processes relevant to metastasis. For instance, 
expression patterns of proteins identified in the OE set complied with our findings about 
the decreased cellular proliferation rate and adhesion characteristics as well as increased 
cellular migration and invasive nature upon CacyBP over-expression. Decreased 
proliferation is known to be coupled with metastatic nature since epithelial 
messenchymal transition (EMT, one of the important phenomenon that happens during 
metastasis), is known to incorporate stem cell properties into cancer cells [286, 287]. 
Similarly reduction in cell adhesion is also an inherent part of EMT caused by the down-
regulation of cell adhesion molecules [46]. Migration and invasion are required to be 
enhanced with increased metastatic potential in order to facilitate the journey of the cell 
through vascular path [20]. However all these phenomena overlap and complement each 
other in order to turn out a successful metastasis. Gene ontology analysis with the 
differentially regulated protein list from the CayBP-OE-iTRAQ dataset (using Ingenuity 
Pathway Analysis software) identified networks associated with enhanced cell migration 
as the two topmost hits. These were i) caveolar mediated endocytosis of integrins and ii) 
Actin nucleation by ARP-WASP complex. The former one can be looked upon as an 
enhanced integrin endocytosis following CacyBP overexpression. As per reported 
literatures, integrin endocytosis is associated with their dissociation from the focal 
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adhesion complex at the rear end followed by their internalization leading to two 
alternative fates [48]: either they are transported back to the plasma membrane of the 
leading edge of the cell body or routed for lysosomal degradation [49]. Transportation of 
integrins to the leading edges of the cell body provides traction for movement and 
thereby increase the cell motility [232]. We found that all integrin subunits identified in 
our OE dataset were up-regulated indicating their gathering at the leading edge and make 
the cell more motile. The later one i.e, actin nucleation via ARP-WASP complex can be 
linked to cell protrusion formation that facilitates cell migration. Actin polymerization 
inducing protein WASP and protrusion formation protein Arp2/3 is directly associated 
with actin polymerization/ de-polymerization cycle which promotes cell migration [34, 
37]. From our CacyBP-OE-iTRAQ dataset, up-regulation of integrin isoforms (α-2 and α-
3) was found to be coupled with this phenomenon. 
 Simultaneously, mining of proteomics data from the KD set interpreted an overall 
reduction in metastatic characters as observed from expression patterns of proteins 
related to focal adhesion, cytoskeleton organization and cellular proliferation. Up-
regulation of proteins positively affecting cell proliferation and adhesion interpreted an 
increase in both whereas altered expression of several actin cytoskeleton associated 
proteins justified the site specific alteration in actin dynamics in a moving cell [38]. 
Altogether, these effects represented an overall suppression in metastatic behavior and 
were in conformity with the results obtained from phenotypic assays. Although gene 
ontology analysis did not identify integrin endocytosis process in its hit list, proteins that 
are essential for integrin internalization were found to be down-regulated upon CacyBP 
knock-down. These include Clathrin heavy chain 1 [49], kinesin KIF4A, Calpain-1 [48] 
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and EH domain-containing protein 1 [273]. Each of these proteins takes part in focal 
adhesion disassembly and integrin endocytosis and hence their down-regulation indicated 
an overall decrease in this process leading to reduced cell motility. Western blot 
validation further confirmed the differential expression pattern of these proteins. At the 
same time, up-regulation of Kinectin, an integral member of focal adhesion and actin 
cytoskeletal assembly [279], implied intensified adherent junctions, further supporting 
the finding about reduction in cell motility upon CacyBP knock-down.  
On the other hand, integrin mediated cell migration is known to be affected by 
intracellular calcium [233, 281], which directed us to investigate the intracellular calcium 
levels in wild type and modified CRC cells. We found enhanced Ca
++
 flux in metastatic 
SW620 compared to primary HCT116 and SW480 cells (Figure 3.10.A), which is in 
conformity with the earlier reports [67]. Additionally, intracellular calcium level was 
increased upon CacyBP over-expression whereas knock-down of CacyBP showed a 
reduced Ca
++
 flux (Figure 3.10.B). This finding can be explained from our proteomics 
data as calcium homeostasis maintaining protein VDAC-1 (Voltage-dependent anion-
selective channel protein 1) was down-regulated upon CacyBP-KD [282]. On the other 
hand, the protease calpain that breaks the linkage between integrin and actin cytoskeleton 
is known to be activated by intracellular calcium (Ca
++
) flux [281].  Therefore the 
reduced intracellular calcium level in CacyBP-KD cells might cause calpain inactivation, 
ultimately leading to impaired integrin trafficking followed by reduced cell migration. 
In conclusion, this study demonstrated that changes in cellular expression level of 
CacyBP provide an impact on metastatic potential of CRC as confirmed from overall 
proteome signatures of both proteomics studies (Figure 3.11.). Moreover integrin 
132 
 
mediated cell migration was found to be the most highlighted phenomenon to be 
enhanced upon CacyBP-OE and reduced upon CacyBP-KD which lead us to conclude 
that CacyBP mediated cell migration is largely affected via integrin endocytosis in CRC. 
ARP-WASP mediated actin nucleation was found to be as important as integrin 
endocytosis since it was validated from both proteomics dataset. We also found a 
plausible role of intracellular Ca
++
 flux in this process. This is the first study to shed light 
on the underlying mechanisms of CRC metastasis induced by CacyBP and thereby 







 Figure 3.11.  Summarizing overall findings from CacyBP-OE and CacyBP-KD iTARQ 
datasets. Proteins indicated in red ink represents up-regulation and those in green ink represents 
down-regulation. CacyBP-OE was shown to enhance overall metastatic signature whereas CayBP-
































4.1. Conclusion of the study 
Lymph node metastasis remained the major concern for death among the colorectal 
cancer patients [9] even though survival rates among CRC patients have increased with 
the use of improved therapeutic strategies, over the past decade [10]. This is due to the 
lack of efficient mode of early detection which is very important to prevent progression 
of the disease. With an aim to fulfil this demand we made the use of proteomics-based 
approaches for both the identification of potential candidate biomarker(s) as well as for 
better understanding of the underlying molecular mechanism of CRC metastasis as 
reported in this thesis. As described in chapter 2, we began with a discovery proteomics 
phase where comparison between whole-cell proteome from primary and metastatic CRC 
cells was performed providing an overall proteome signature for CRC metastasis as well 
as proposal for novel candidate proteins as biomarkers. Among these, the low expression 
level of β-catenin combined with the up-regulation of CacyBP (Calcyclin binding 
Protein), a β-catenin degrading protein, in the metastatic cell provided a rational guide for 
choosing CacyBP as a potential candidate protein and performing subsequent 
downstream functional assays on it. The low expression level of β-catenin both in the 
cytoplasmic as well as the nuclear fractions from the metastatic cell (Supplementary 
figure 4.1., appendix) combined with the up-regulation of CacyBP, suggested a possible 
involvement of these two proteins in CRC metastasis either via the alteration of β-catenin 
(cytoplasmic) mediated cellular adhesion or the regulation of the transcription levels of β-
catenin (nuclear) controlled downstream target proteins. However, role of CacyBP in 
cellular proliferation and tumorigenesis via β-catenin mediated downstream nuclear 
effectors are vastly studied by many groups [179, 222, 288]. Therefore we focused our 
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study towards investigating the role of CacyBP on cytoplasmic β-catenin mediated 
cellular adhesion since this field was rarely explored and also due to the strong 
correlation between reduced adhesion characteristics and metastatic phenotype. 
Preliminary functional studies (Transient over-expression of CacyBP in primary CRC 
cells and adhesion assay performed on them) proved the hypothesis that raised CacyBP 
level in metastatic CRC cells caused increased degradation of β-catenin and thereby 
reduce cellular adhesion characteristics. Experiments were performed on several primary 
CRC cells in order to confirm the above phenomenon. However, for better understanding 
of other molecular phenomena behind the involvement of CacyBP in CRC metastasis, we 
performed stable gene knock-in and knock-down experiments on CRC cells. Forced 
expression of CacyBP on primary CRC cells increased its metastatic nature as observed 
from cell migration, invasion, adhesion and proliferation assays. On the other hand, 
knock-down of CacyBP on metastatic CRC cells resulted in opposite effects further 
confirming the hypothesis that increased expression of CacyBP is associated with CRC 
metastasis. To further investigate the detailed mechanism through which CacyBP induces 
metastasis, additional proteomics experiments were performed on CacyBP- OE and 
CacyBP-KD cells that provided a new direction. It was observed that integrin endocytosis 
was enhanced upon CacyBP over-expression and reduced upon CacyBP knock-down. 
Integrin endocytosis could be either caveolar or clathrin mediated [49] and resulted in 
dissociation of integrins from focal adhesion complex at the rear end adherent junction of 
a cell body. These dissociated integrins were then either transported back to the leading 
edges of a moving cell or undergo lysosomal degradation [48]. Up-regulation of integrins 
combined with identification of caveolar mediated endocytosis as the topmost network in 
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CacyBP-OE cells confirmed that endocytosed integrins did not undergo lysosomal 
degradation, instead trafficked towards the leading edges of the cells that provided the 
traction force for cellular movement [232] resulting in enhanced cell motility. Increase in 
intracellular calcium level upon CacyBP-OE and its drop upon CacyBP-KD also 
connected integrin signalling with CacyBP mediated cell migration [233]. 
Simultaneously, actin nucleation via WASP-ARP complex was the second hit among the 
pathways regulated upon CacyBP-OE and hence can be looked upon as another 
mechanism behind enhanced cell migration [33, 38]. Phenotypic assays performed on 
CacyBP-OE and CacyBP-KD cells showed a reduced proliferative and adhesive nature 
with an increase in its migration and invasion ability upon over-expression, whereas 
opposite phenotypes were observed upon knock-down.  Hence all these observations 
together proved that CacyBP plays an important role in the promotion of CRC metastasis. 
Therefore in conclusion, our study identified CacyBP as one of the potential candidate 
biomarkers for CRC metastasis and proved that, its increased level is associated with 
disease progression. Additionally, it was derived that increased CacyBP level either cause 
the cells to become less adherent by decreasing the β-catenin level via proteosomal 
degradation, or made the cell more motile by enhancing the cell migration characteristics. 
In short, this study identified CacyBP as a potential candidate protein for the biomarker 
analysis of CRC metastasis as well as shed light on the possible mechanism behind its 





4.2. Future directions of the project  
Since CacyBP is a comparatively new candidate protein in the field of CRC research, 
several research opportunities still exist in its way to verify its role as a diagnostic marker 
or therapeutic target. We highlighted few alternative directions here. 
4.2.1. Validation of CacyBP expression level in patients from different stages of 
CRC 
 Background of study: As mentioned in chapter 2 and 3, our study illustrated an 
increased expression level of CacyBP associated with CRC metastasis and we have 
validated this observation in cell based models. However, in order to establish 
CacyBP as a potential candidate biomarker, clinical validation is necessary. 
Immunohistochemistry performed on non-tumor versus tumor tissue samples from 
patients of renal cell carcinoma showed positive staining for CacyBP in all non-tumor 
samples whereas weak or absent stain were observed in renal cell carcinoma tissues 
[222]. On the contrary, similar investigation on breast cancer samples showed 
opposite results. mRNA and protein levels of CacyBP was significantly higher in 
breast cancer tissues compared to adjacent non-tumor tissues. Poor cellular 
differentiation, lymph node invasion, clinicopathological staging and also recurrence 
and metastasis in breast cancer were found to be associated with CacyBP expression 
[230]. However immunohistochemical studies on CRC stages are not yet reported and 
hence could be considered as one of the future directions of this project. 
 Design of experiments: Immunohistochemical staining against CacyBP will be 
performed on patients‟ tissue and serum samples from different stages of CRC in 
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order to confirm the correlation between CacyBP expression level and CRC disease 
progression especially metastasis. 
4.2.2. Identification of nuclear binding partners of CacyBP  
 Background of study: CacyBP is known to interact with several binding partners 
[289]. However novel downstream nuclear binding partners are yet to be identified 
which may open new directions for understanding the mechanism involved. We 
observed high abundance of CacyBP in the nuclear compartment of metastatic cells 
whereas in the primary cells, the protein is mainly located in the cytoplasmic 
component (Figure 4.1.A). When verified using western blot approach, similar results 
were obtained (Figure 4.1.B). This indicates nuclear translocation of CacyBP during 
metastasis. On the other hand, it has been reported that CacyBP is mainly present in 
the cytoplasmic component of the CRC cells and translocated to the nucleus with a 
raise in intracellular calcium level [231]. Our priliminary study with primary and 
metastatic CRC cells for intracellular calcium level demonstrated that metastatic cells 
has an enhanced Ca
++
 flux compared to primary cells (Figure 3.10.). Combining this 
observation with the reports from existing literature lead to the hypothesis that 
CacyBP translocates to the nucleus due to the higher calcium level in the metastatic 
cells. Hence it might be interesting to find out new binding partners for CacyBP from 
the nuclear fractions of the metastatic cells as it might be associated with some 
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 Design of experiments: Identification of CacyBP binding partners from nuclear 
fractions of the metastatic CRC cells, are to be performed by immunoaffinity pull-
down experiments on the corresponding fraction using CacyBP antibody and the 
resulting protein mixture will then be analyzed using MS/MS to identify novel 
binding partners. Identified proteins will be further subjected to validation using 
western blot or immunofluorescence approaches. 
4.2.3. Integrin endocytosis and trafficking to the leading edge, majorly induced by 
CacyBP overexpression is one of the important reasons behind CRC metastasis 
 Background of study: As described in chapter 3, our proteomics analysis on CacyBP 
over-expressed and knock-down CRC cells showed a good correlation between 
Figure 4.1.  CacyBP expression level in cytoplasmic and nuclear fraction from primary 
(SW480) and metastatic (SW620) CRC cells. A) CacyBP protein level in nuclear compartment of 
SW620 cells was higher than in the nuclear compartment of SW480 cells as shown by 
immunofluorescence. B) Western blot with the nuclear and cytoplasmic fractions from both SW480 
and SW620 cells showed an enhanced CacyBP level in SW620- nuclear fraction compared to 
SW480- nuclear fraction. GAPDH was used as a loading control for cytoplasmic proteins. 
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integrin endocytosis and enhanced metastatic nature upon CacyBP over-expression 
on primary cells. Review of existing literature helped to build in an hypothesis that 
enhanced integrin endocytosis in CacyBP over-expressed cells is due to the 
dissociation of integrins from the focal adhesion complex of the rear end cell surface 
and these dissociated integrins are then transported back to the leading edge of the 
cell facilitating cell migration [48, 49]. However in order to prove this hypothesis, 
following molecular cell biology-based experiments can be conducted. 
 
 Design of experiments: Initially, specific integrin isoforms are to be validated for 
their expression level in CacyBP over-expressed cells either via western blot or 
immunofluorescence analysis. Since it might be quite challenging to obtain a highly 
specific antibody for integrin isoforms, an alternative way of validation could be mass 
spectrometry-based MRM (multiple reaction monitoring) approach. Since literature 
reported that integrin α6β4 is found to be redistributed in migratory epithelial cells 
[290] and our proteomics study also identified α6 integrin isoform as one of the up-
regulated ones, the downstream experiments can be designed on α6 integrin. In order 
to establish the integrin turnover in CacyBP over-expressed cells compared to the 
corresponding control cells, ELISA (quantitative) or western blot (semi-quantitative)-
based integrin internalization assay are to be designed. Figure 4.2. gives a schematic 































The assay is based on the following principles: a) Cross-linking: intact cells are to be 
incubated with primary (integrin-specific) and biotinylated secondary antibody and kept 
strictly at 4°C to prevent endocytosis; b) Internalization: cells are to be placed at 37°C 
to facilitate internalization and reactions are to be stopped at various time points; c) 
Masking: biotin residues (i.e. not internalized biotinylated secondary antibody) on the 
cell surface are to be masked with excess avidin. Free binding sites on the tetravalent 
Figure 4.2.  Schematic representation of the assay used to monitor 
internalization of integrins. A) Step1- crosslinking; B) Step2- Internalization; C) 
Step3- Masking; D) Step4- Lysis and detection (Inspired by the strategies described 
by Gaietta, G., et al. [290]) 
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avidin molecule are to be saturated with biocytin, a biotin analog; d) Lysis+ Detection: 
cells are to be lysed and the lysate is added to ELISA plates coated with an antibody able 
to bind the biotinylated secondary antibody. Only internalized secondary antibody still 
has available biotin residues, protected during the masking step, which are measured 
using the HRP-streptavidin detection system [290]. Alternatively, the cells can be lysed 
using an immunoprecipitation compatible buffer followed by precipitation of the 
biotinylated proteins with streptavidin-agarose and analysis using western blot [291]. 
Similarly, localization of the internalized integrins can be monitored microscopically by 
tagging the biotinylated proteins with suitable fluorescent antibodies.  
4.2.4. Mechanistic investigation on altered intracellular calcium flux upon CacyBP 
expression level change 
 Background of study: Our study showed that intracellular calcium level is enhanced 
upon CacyBP over-expression and is reduced upon CacyBP knock-down and the 
enhanced Ca
++
 flux inside the cell is directly associated with CRC metastasis and 
enhanced integrin endocytosis and recycling. This observation leaves further scope of 
study about the detailed mechanism behind CacyBP- regulated intracellular Ca
++
 flux. 
On the other hand, CacyBP is known to interact with several binding partners and the 
functional implications of most of the interactions are known except for S100 family 
proteins [289]. As mentioned earlier, CacyBP was discovered as a binding partner of 
calcyclin or S100A6 and later on it was shown that this interaction is highly calcium 
dependent. In fact the interaction takes place only at certain range (0.01 µM to 39.8 
µM) of physiological Ca
++ 
concentration [225]. This background information can be 
used in conjunction with our observation on CacyBP dependent Ca
++
 flux in CRC 
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cells to build the hypothesis that CacyBP-S100A6 interaction might play important 








 Design of experiments: It is known that the fragment of CacyBP protein 
encompassing the residues from 178-229 amino acids are responsible for full binding 
to S100A6 [226]. In order to find out whether this interaction affects the calcium 
dynamics in CRC cells, constructs of CacyBP lacking the sequence of 178-229 will 
be generated and expressed in CRC cells. The truncation should not be performed 
within the intermediary regions of the two helices existing in 163-175 and 188-200 
amino acid (Supplementary figure 4.2., appendix) residues since it may hinder proper 
folding of the truncated protein. Hence amino acid residues 163-229 will have to be 
removed for the generation of the truncated construct. The interaction between 
S100A6 and truncated-CacyBP will be verified and compared with cells 
overexpressing the full length protein. Corresponding Ca
++
 flux will be measured 
using fluo-3AM staining as described in chapter 3. S100A6-CacyBP interaction 
should be interrupted upon truncation and it is to be monitored that whether there is a 
change in corresponding Ca
++
 flux due to this binding interruption. 
Figure 4.3.  Interaction of CacyBP with different binding partners and their implications 



























4.2.5. CacyBP and CRC metastasis- A dose dependent correlation 
 Background of study: Our study showed that higher level of CacyBP is associated 












 Design of experiments: Different levels of CacyBP will be over-expressed in 
multiple primary CRC cells and the over-expressed cells will be tested for their 
metastatic nature by cell based assays. The quantitative measurement about the 
metastatic nature will be plotted against the level of over-expression of CacyBP. This 




Figure 4.4.  Preliminary data correlating cellular CacyBP level with metastatic 
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Supplementary figure 2.1. 
 
Supplementary figure 2.1. Flow-cytometric detection of cell population at G1, S and G2 







Supplementary figure 2.2.   
 
 
Supplementary figure 2.2.  Original exported image from IPA for the functional 
networks associated with the significantly altered proteins. Cellular assembly and 











Supplementary figure 2.3. 
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Supplementary figure 2.3. Adhesion assay for same number of SW480 and SW620 cells 













Supplementary figure 3.1. 
 
Supplementary figure 3.1.  Original exported image from IPA for the functional 
networks associated with the significantly altered proteins. Caveolar mediated 
endocytotic signaling was the topmost and actin nucleation was the second. 
 
Supplementary figure 4.1. 
 
Supplementary figure 4.1.  β-catenin level was reduced both in cytoplasmic and nuclear 
fractions from metastatic cells. 
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Supplementary figure 4.2. 
 
Supplementary figure 4.2.  Secondary structure prediction for CacyBP protein by 
PSIPRED 
